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Estrogens have been implicated to take part in the normal and abnormal growth 
of the prostate. In the Noble (Nb) rat model, the use of estrogen alone or combined use 
with androgen can induce carcinoma in the prostate. However, the exact role of 
estrogen in prostate function and prostate carcinogenesis is still unclear. Therefore, 
estrogen carcinogenicity in the prostate was investigated using both in vitro and in vivo 
models in this study. 
Methodology 
In the in vitro study, a normal immortalized and non-tumorigenic rat prostatic 
epithelial cell line, NRP-152, was treated and transformed by IVP-estradiol (E2). 
Anchorage independent growth, doubling time (DT) and colony-forming efficiency, 
differential gene expression, protein expressions (estrogen receptor a [ERa], estrogen 
receptor (3 [ERP], androgen receptor [AR], tubulin-a, PTEN, Rap 1, BRCA2, and 
superoxide dismutase [SOD-1]) by immunohistochemistry and Western blottings, 
ultrastructural study and tumorigenicity were studied and compared among the 
parental and E2-transformed NRP-152 cells. 
In the in vivo study, male Nb rats were treated with estrogen perinatally followed 
by a combined hormone treatment at adulthood. Morphological changes and protein 
expressions (ERa, ERp, AR, PTEN, Rap 1, BRCA2, tubulin-a and SOD-1) by 
immunohistochemistry were examined. 
Results 
In the in vitro study, formation of colonies in soft agar with a higher efficiency, 
ii 
Abstract 
increased DT, distorted cellular ultrastructure and altered protein expressions were 
observed in the Ei-transformed NRP-152 cells. However, inoculation of 
E2-transformed NRP-152 cells developed no sign of tumor growth. 
In the Nb rat model, perinatal estrogen exposure with hormone treatment at 
adulthood could induce premalignant and malignant lesions in the ventral prostates 
(VP) and the lateral prostates (LP). Neoplastic lesions in the dorsal prostate (DP) 
where abnormal lesions were rarely induced by hormones were also observed. Altered 
protein expressions were found. 
Discussion 
The in vitro study suggests that estrogen may transform prostatic epithelial cells 
as E2-treated cells can form colonies in soft agar with a higher colony-efficiency. 
Besides, ultrastructural study suggests that E2 may transform prostatic cells by 
estrogen metabolites or disrupting microtubules. The in vivo study shows that peinatal 
exposure to estrogen may enhance the severity and susceptibility of prostatic lesions in 
Nb rats further treated with hormones at adulthood. 
Altered ERa, ERP and AR expressions show that estrogen, rather than androgen, 
may predominantly regulate prostatic cell growth via the increased expression of ERa. 
Decrease in tubulin-a expression after estrogen exposure suggests aberrations in 
chormosome segregation during cell division. Altered protein expressions of PTEN, 
Rap 1, BRCA2 and SOD-1 may postulate that estrogen may trigger cellular defense 
mechanism initially but then induce transformation or prostatic lesions by 
down-regulating these tumor suppressor proteins or the scavenging enzyme. 
Conclusion 
In the in vitro study, we showed that estrogen might transform the NRP-152 cells. 
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However, prolonged estrogen treatment may be required for the development of 
tumorigenicity. In the in vivo study, we demonstrated that early estrogen exposure 
increased the severity and susceptibility in developing prostatic lesions in Nb rats 
further treated with hormones. However, how exactly estrogen transforms the normal 
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Chapter 1. Introduction 
1.1 Developmental biology of the prostate 
1.1.1 Development of prostate gland in humans and rodents 
Prostate gland is the largest male accessory gland. It is an exocrine gland and 
its secretion contributes about one-third of the seminal plasma. The development, 
growth and function of the prostate are androgen-dependent. The prostate gland 
develops from the urogenital sinus. During fetal period, androgen is produced by the 
fetal testes to initiate the development and branching morphogenesis of the prostatic 
buds. The prostatic buds emerged from the urogenital sinus elongate and grow in the 
surrounding mesenchyme (Kellokumpu-Lehtinen et al, 1980). 
In humans, prostatic ducts originate from urethra at specific anatomical sites 
(Lowsley, 1912). Different zonal subdivisions of the prostate are developed and 
emerged into anterior fibromuscular stroma, peripheral zone, central zone and 
transitional zone. Epithelial outgrowths arise from prostatic urethra around 10th 
week of gestation. Prostatic ductal morphogenesis and growth occur prenatally and 
pubertal!y (Zondek & Zondek, 1975). Pathological growth of benign prostatic 
hypertrophy (BPH), an enlargement of prostate, is initiated at old age (Coffey et al, 
1987). Prostatic diseases are zone-specific. For example, prostatic adenocarcinoma 
arises mostly in peripheral zone while BPH develops from transitional zone and 
periurethral gland (Cunha et al, 1987). 
In rodents, prostatic buds arise from different parts of the endodermal 
urogenital sinus, giving rise to individual lobes (ventral, dorsolateral and anterior) 
located in specific positions around urethra. Prostatic buds appear late in the 17th day 
of gestation (vaginal plug = day zero) in mouse fetuses and 18-19th day of gestation 
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in rats (Price & Ortiz, 1965). Each prostatic lobe has its own distinctive ductal 
branching pattern. Unlike humans, prostatic growth and ductal morphogenesis are 
continuous from fetal life to sexual maturity. 
Masculine differentiation of hypothalamus is necessary for the development 
of a male reproductive system. For newborn male rats, the sensitive period to 
defeminizing the action of androgen is right after birth (Corbier, 1985). In this 
critical time period, an appropriate amount of testosterone would lead to the 
masculine differentiation of hypothalamus which would in turn regulate the 
development of a male reproductive system as shown in rats and mice (Limanowski 
et al, 1994; Dalterio et al, 1985). An inadequate amount of androgen in male rats and 
mice within the perinatal period would result in changes in the reproductive system 
(Limanowski et al, 1994). 
1.1.2 Mesenchymal-epithelia丨 interaction 
Mesenchymal-epithelial interaction is involved in the development of 
prostate. It refers to a cell-cell interaction initiated during fetal period. Epithelial-
mesenchymal interaction is essential in the development of the male urogenital tract. 
The interaction between the urogenital mesenchyme (UGM) and the urogenital 
epithelium (UGE) leads to the prostatic development with the presence of androgen 
(Cunha et al, 1987). Through this interaction, the undifferentiated connective tissue, 
mesenchyme, induces epithelial development and vice versa, i.e. epithelium induces 
mesenchymal differentiation (Cunha et al, 1992; Hay ward et al, 1996). The adult 
counterpart to mesenchymal interaction is the so-called 'stromal-epithelial 
interaction' (Hayward et al, 1996). Prostate develops due to the interaction between 
urogenital mesenchyme and urogenital epithelium in the presence of androgen. An 
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altered or unbalanced interaction between the tissue components can lead to or be 
involved in the development of BPH and prostatic carcinogenesis (Hayward et al, 
1996). 
1.2 Overview of endocrinology of prostate 
The normal development of the prostate is androgen-dependent. During fetal 
period, the developing testes produce androgen for prostatic morphogenesis. The 
testosterone produced by fetal testes would be reduced by 5a-reductase to 
dihydrotestosterone (DHT) within urogenital sinus (Cunha et al, 1987). DHT is an 
active and potent intracellular androgen responsible for prostate morphogenesis. 
After birth, there is a growth-quiescence of prostate as androgen level is low. 
At puberty, the androgen level increases to initiate sexual maturation and the 
appearance of secondary sex characters. As a result of the rise in androgen level, 
prostatic growth is triggered again at puberty (Coffey et al, 1987). Further prostatic 
growth ceases at adulthood. However, androgen production is necessary for the 
continued maintenance, morphological and functional activity of the prostate gland. 
The production of androgen is under endocrine control. Androgen, or testosterone 
(T), is produced by the testes. Its production is stimulated by two gonadotropic 
hormones, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), 
secreted by the anterior pituitary gland. The release of these two hormones is further 
controlled by the gonadotropin-releasing hormone (GnRH) secreted by the 
hypothalamus. The level of testosterone production is regulated by a negative 
feedback control (Shupnik, 1996). Above-normal testosterone level would inhibit the 
release of GnRH, resulting in a reduced release of LH and thus lowering the 
3 
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testosterone level. At old age, the level of testosterone is reduced (Bosland, 2000) as 
aromatase converses testosterone into estradiol. 
The importance of androgen for the prenatal and postnatal development of 
prostate can be demonstrated in several ways. Ablation or surgical removal of fetal 
testes, which removes the supply of androgen, would inhibit the development of 
prostate (Jost, 1953; Cunha et al, 1987)). Besides, chemical castration by using high 
doses of estrogens or GnRH antagonists, which blocks the axis between 
hypothalamus and pituitary, inhibits the prostate development. During postnatal 
period, castration of neonatal mice or rats would inhibit the development of prostate. 
Moreover, castration of adult male rats results in regression or atrophy of prostate. 
Regression of gland is found to be about 10% of the original size (Lee, 1981). These 
phenomena show that androgen is highly related to the prostate development and 
growth at fetal stage and adulthood. 
1.3 Estrogen in male and prostate gland 
Apart from androgen, estrogen may play a role in the development and 
growth of prostate. However, its exact role in the prostate remains unclear and 
controversial. The plasma of adult males contains a small amount of estradiol. Most 
of the estradiol in adult males is formed from the circulating testosterone. The 
remaining is secreted from testes (10-20%). At elderly, estradiol is converted from 
testosterone by aromatase. Thus, estradiol level increases with age in males. Estrogen 
may play a role on prostate gland as it has both stimulating and inhibitory effects on 
the growth and differentiation of prostate gland (Farnsworth, 1996). 
1.3.1 Stimulating effect of estrogen on prostate gland 
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Estrogen can exert a stimulating growth effect on prostate. One of the early 
evidence comes from the animal studies that hypertrophy of epithelial cells can be 
induced in castrated or hypophysectomized dogs by the use of estrogen (Leav et al, 
1978; Kwan et al, 1982). 
Similar stimulating effect of estrogen is found by Salander and Tisell (1976) 
and Thompson et al (1979). An increase in the height of epithelial cells is observed 
in the ventral prostate after estrogen treatment. 
Moreover, epithelial proliferation is enhanced by the combined estrogen and 
androgen treatment in the intact Nobel rat prostate (Leav et al, 1989) 
Pelletier (2002) also illustrates that administration of estrogen can stimulate 
the mRNA expression of PBP CI, a prostate binding protein, in the prostate gland of 
adult castrated rats as well as castrated rats treated with DHT and with a combination 
of DHT and estrogen. This study shows that estrogen can exert a stimulatory effect 
directly on the prostate epithelial cells in the absence or presence of androgen 
(Pelletier, 2002). 
Besides，pharmacological doses of estrogen can induce squamous metaplasia, 
a marked proliferative alteration of prostate epithelium, in the prostate (Leav et al, 
1978; Mawhinney & Neubauer, 1979). It has also been shown that estrogen can 
directly induce squamous metaplasia in the regressed prostate of castrated or 
hypophysectomized dogs (Leav et al, 1978). 
In the developing prostate of human fetuses, squamous metaplasia occurs 
spontaneously at about 22 weeks of gestation, probably due to the high level of 
maternal estrogen (Andrews, 1951). 
1.3.2 Inhibitory effect of estrogen on prostate gland 
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Paradoxically, pharmacological doses of estrogen can exert an inhibitory 
effect on the prostatic cells. Estrogen can act on the hypothalamus-pituitary axis to 
suppress the secretion of gonadotropins, resulting in a decrease in testicular androgen 
production (Muggins & Hodges, 1972). The down-regulated circulatory level of 
androgen would then inhibit the development of prostate. Based on this mechanism, 
the inhibitory effect of chemical castration by estrogen has been applied to the 
prostate cancer therapy. A synthetic estrogen, diethylstilbestrol (DES), have been 
used to treat prostate cancer patients (Huggins & Hodges, 1941) in order to reduce 
the blood level of testosterone that is required for the growth of prostate cancer by 
preventing the release of pituitary gonadotropic hormones that control the testicular 
production of testosterone. 
1.4 Study of the role of estrogen receptors in prostate gland with 
the use of estrogen receptor knockout mice 
1.4.1 The two isoforms of estrogen receptors (ER): ERa and ERp 
The effect of estrogen in prostate gland can be mediated through the 
expression of estrogen receptors, estrogen receptor alpha (ERa) and estrogen 
receptor beta (ERp), in the prostate gland. ERa and ERp are the two isoforms of ER. 
They are highly homologous in the DNA-binding domain but they differ in the 
ligand and transactivation domains. ERf is cloned from the rat prostate (Kuiper et al, 
1996) and mouse ovary (Tremblay et al, 1997). This cDNA is distinct from the 
classical ERa cDNA (Kuiper et al, 1997). ERa is predominately expressed in the 
mesenchymal cells in the proximal region of the prostate gland (Cooke et al, 1991; 
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Prins & Birch, 1997) while ERP is mostly found in the prostatic epithelium (Kuiper 
et al, 1996; Kuiper et al, 1997). 
1.4.2 The use of estrogen receptor knockout mice for the study of ER 
Estrogen receptor knockout (ERKO) mice are transgenic mice with targeted 
deletion of ERa (aERKO) (Lubahn et al, 1993; Couse & Korach, 1999) or ERp 
(Kerge et al, 1998). The use of these knockout mice allows the study of the specific 
roles of ERa and ERp playing in the prostate gland. 
(a) ERa as a mediator in estrogen imprinting and prostatic lesions 
In a study using ERKO mice, wild-type (WT), aERKO and |3ERKO mice are 
treated with DES postnatally for the study of estrogen imprinting (Prins et al, 2001a). 
After being exposed to estrogen, WT mice exhibit estrogen imprint effects as 
epithelial dysplasia is induced in ventral and dorsolateral prostate with aging. On the 
contrary, no evidence of estrogen imprinting is found in the aERKO mice after the 
estrogen exposure, even at old age. pERKO mice also exhibit estrogenization effects 
as the WT mice did (Prins et al, 2001a). These findings by Prins et al (2001a) 
suggest that ERa, rather than ERp, is dominated for the mediation of estrogen 
imprinting in the prostate gland at time of neonatal exposure. 
In addition, Risbridger et al (2001) finds that prostatic squamous metaplasia 
can be induced by DES for three weeks in the prostate glands of the WT and pERKO 
mice but not in the aERKO mice. This study suggests that ERa is involved in the 
formation of prostatic lesions induced by estrogenic responses in prostate gland. 
(b) ERp as an inhibitor in the growth of prostate 
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The role of ERp in the prostate gland has also been studied in the ERKO 
mice. Studies show that ERp may be responsible for the negative regulation in the 
growth of the prostate gland. One of the reasons of ERP is considered to play an 
antiproliferative role in prostate comes from the study by Krege et al (1998). In their 
study, ERp knockout mice display prostate hyperplasia with aging, suggesting that 
ERp may act to inhibit abnormal growth of the prostate gland. 
The down-regulation of ERp expression during prostatic carcinogenesis and 
tumor progression also illustrates that ERp may normally inhibit the growth of 
prostate as its decrease leads to prostate cancer development (Leav et al, 2001). 
Another support for ERp as an inhibitor of prostate growth is demonstrated 
by the use of anti-estrogens (Lau et al, 2000). It has been found that anti-estrogens 
inhibit proliferation in prostatic cancer cells which express ERP. As estrogen has to 
exert it effects via its receptors, this finding shows that ERp is involved in the anti-
proliferation of prostatic cells. 
1.5 Estrogen as a carcinogen 
Estrogen is a well-known promotor in carcinogenesis as shown in the animal 
models of breast, endometrical, kidney and liver cancers. The formation of DNA 
adducts and oxidants (reactive oxygen radicals, ROS) and the disruption of 
microtubules are considered to be the inducing mechanism involved in the estrogen 
carcinogenicity. 
1.5.1 Formation of DNA adducts 
Estrone (Ei) and estradiol (E2) are biochemically interconvertible. They can 
be metabolized via two major pathways: 16a-hydroxylation and the formation of 
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catechol estrogen (CE). CE may be oxidized to semiquinone (CE-SQ) and quinone 
(CE-Q). CE-Q may be catalyzed by S-transferase to conjugate with glutathione or be 
reduced to CE by quinone reductase for the inactivation of CE-SQ and CE-Q. If 
inactivation is not completed, CE-2,3-Q may react with DNA, forming a stable DNA 
adduct while CE-3’4-Q may form a depurinating adduct (Stack et al, 1996; Cavalieri 
et al, 1997; Cavalieri et al, 2000). When the glycosidic bonds are cleaved, these 
adducts are lost from DNA and apurine sites are formed (Cavalieri et al, 1997). 
Apurine sites would cause mutations that lead to cancer development. Thus, estrogen 
can initiate tumor formation through the formation of DNA adducts from CE. 
1.5.2 Formation of oxidants 
Excess oxidants can be removed by cells as they possess antioxidant defenses. 
However, when reactive oxygen species (ROS) are generated at an inappropriate 
time, in excess amounts or when antioxidant defenses are overwhelmed, oxidants 
would induce damaging effects in cells (Cavalieri et al, 2000). Genetic materials 
may be oxidatively modified by oxidants. 
Redox cycling of catechols (CE), quinones (Q) and semi-quinones (SQ) are 
capable when molecular oxygen is available. Therefore, substantial production of 
ROS is allowed even there is a small amount of estrogen (Cavalieri et al, 2000). The 
production of ROS may then cause cell damage. 
ROS may cause oxidative damage of cellular macromolecules, like proteins 
and lipids, other than DNA (Cavalieri et al, 2000). Estrogen-induced ROS can have a 
pronounced influence on the maintenance of the functioning of cells as redox-
sensitive centers of the anti-oxidant and repair enzymes are readily modified by 
prooxidant changes (Ding & Demple, 1997; Cavalieri et al, 2000). Besides, lipid 
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hydroperoxide derived aldehydes interact with bases in cellular DNA, giving rise to 
DNA modification (Wang & Liehr, 1995; Cavalieri et al, 2000). 
Oxidants may interplay with estrogen metabolites resulting in DNA base 
damage. These damages include the formation of DNA base adducts from quinones, 
lipid hydroperoxide-derived aldehyde DNA adducts and a plethora of oxidized DNA 
bases. 
During estrogen metabolism, hydrogen peroxide (H2O2) is generated by the 
redox cycling of semiquinone-quinone couple which is readily reduced by cellular 
transition metal ions, e.g. Cu^^ and Fe^^, to the most potent oxidants, hydroxy! 
radicals (•OH). 
Hydroxyl radicals are so potent as they do not just oxidize bases in DNA, but 
also cause lipid peroxidation. Lipid hydroperoxides formed may act as cofactors in 
later estrogen metabolism, leading to additional and continuous semiquinone-
quinone redox cycling and ROS production. Cellular damage is then amplified. 
The hypothesized relationship of estrogen and cancer initiation is illustrated 
in Figure 1.1. 
1.5.3 Estrogen as a microtubule-disrupting agent 
DES has been shown to be a microtubule-disrupting agent. The in vitro use of 
DES exhibits transforming and genotoxic activities in cultured mammalian cells 
(Danford & Parry, 1982; Tsutsui et al, 1983). Polymerization of microtubules is 
found to be disrupted by DES treatment and as a result aneuploidy is induced 
(Tsutsui et al, 1983; Tucker & Barrett，1986). As aneuploidy induction correlates 
well with cell transformation (Li et al, 1997), the conformational and functional 
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changes in microtubule organization are suggested to be responsible for the induced 
aneuploidy and transformation in cells. 
Tsutsui et al (2000) also demonstrates that 2-methoxyestradiol (2-MeOE2)’ an 
endogenous metabolite of estrogen, can induce morphological transformation, 
somatic mutation and/or chromosomal abnormalities in Syrian hamster embryo (SHE) 
cells. These alteration are achieved by the binding of 2-MeOE2 to the colchicine site 
of the tubulin which in turn inhibits microtubule assembly (D'Amato et al, 1994). 
Abnormal microtubule formation in cytoskeleton and in spindle figure is observed 
after DES treatment and this may lead to the induction of multinucleation and 
aneuploidy in SHE cells (Tsutsui et al, 2000). This study indicates that endogenous 
metabolites of estrogen, like 2-MeOE2 is able to cause transformation and exert 
genotoxic effects in cultured mammalian cells. Therefore, estrogen and its 
metabolites may possess potential carcinogenic activity in target cells (Tsutsui et al, 
2000). 
1.6 Estrogen carcinogenicity in animal models 
Estrogen is well documented to be a tumor initiator in a number of tumors as 
shown by its carcinogenicity induced in different animal models. 
1.6.1 Syrian golden hamster model 
(a) Kidney cancer 
Kidney cancer can be induced by estrogen in the Syrian golden hamsters. 
Bilateral renal tumor can be induced after estrogen treatment in both intact and 
castrated male hamsters, with approximately 100% incident rate (Kirkman, 1959). 
The induced tumors are hormone-dependent but of uncertain origin (Li & Li, 1990) 
(b) Liver cancer 
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Hepatic neoplasms can be induced by synthetic estrogens, like 
ethinylestradiol (EE) and DES, in male hamsters after chronic hormonal treatment 
(Li&Li，1987). 
1.6.2 Rat model 
Another animal model related to estrogen carcinogenicity is the rat model. 
The Noble (Nb) rat model has been used in the study of hormonal carcinogenesis as 
this rat strain is susceptible to tumor induction by estrogen. Treatments with estrogen 
alone can induce tumors in various tissues in this rat strain, such as pituitary gland, 
uterus, mammary gland, prostate gland and testes (Noble, 1982). Among these, the 
role of estrogen in mammary carcinogenesis is well studied (Cheung et al, 2003). 
The estrogen-induced mammary tumors are hormone-dependent, suggesting that the 
involvement of estrogen in mammary carcinogenesis. The growth of mammary 
tumors can be prevented after the removal of ovaries, a source of estrogen in females. 
Induction of mammary tumors can also be achieved in female rats using a 
combination of estrogen and testosterone (Xie et al, 1999a; Xie et al, 1999b; Cheung 
et al, 2003). A high incidence of breast cancer with a shorter latency period can be 
achieved in female Nb rats after prolonged exposure to this combined hormonal 
treatment (Xie et al, 1999a; Xie et al, 1999b). Testosterone is found to affect only the 
latency period but not the incidence in mammary carcinogenesis (Xie et al, 1999b). 
Thus, it is hypothesized that in the simultaneous use of estrogen and testosterone in 
mammary tumor induction, estrogen acts as a predominant initiator while 
testosterone as a major promoter (Xie et al, 1999a). 
1-7 Animal models of prostate cancer by hormonal induction 
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There are several animal models in the study of prostate cancer by the use of 
hormone. 
1.7.1 Canine model 
Dog is the only animal that can develop spontaneous prostate cancer, as 
compared to rats and mice (Noble, 1982). Histologically high grade prostate 
carcinoma and high grade prostatic intraepithelial neoplasia (PIN) can be found in 
elderly intact dogs (Waters et al, 1997). 
Prostate cancer can be induced in dogs with the combined use of hormones. 
Walsh and Wilson (1976) demonstrate that combined use of 3a-androstanediol and 
estradiol can enhance prostatic growth in mongrel dogs, as compared to the use of 
3a-androstanediol alone. The enhanced stimulatory prostatic growth by the 
simultaneous use of estradiol and DHT is also confirmed in the pure bred beagles 
(DeKlerk et al, 1979; Ehrlichman et al, 1981). These studies demonstrate that 
estrogen is involved in the development of prostatic diseases (particularly benign 
prostatic hyperplasia, BPH) in canines. 
Nevertheless, it is difficult to study prostate cancer with canine model as 
there is a lack of control in the dog population that will develop prostate cancer and 
subsequently the bone metastases (Navone et al, 1999). 
1.7.2 Noble rat model 
(a) The combined use of testosterone propionate (TP) and estrone (Ei) in 
prostate cancer induction 
Noble (Nb) rat strain develops spontaneous prostate cancer at a very low 
incidence rate (Noble, 1982). Noble reports that with the use of multiple testosterone 
propionate (TP) pellets in Nb rats, an increase in incidence of prostate cancer in 
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dorsolateral prostate is observed (Noble, 1982). Interestingly, a 50% incidence can 
be achieved if TP is removed and substituted with an estrone (Ei) pellet after 52 
weeks (Noble, 1982). 
(b) The use of testosterone and 17p-estradioI filled Silastic implants in 
prostate cancer induction 
In a study performed by Drago (1984), microscopic carcinomas can be 
observed in the dorsolateral prostates in 88% of intact Nb rats after being treated 
with testosterone (T)-filled and 17P-estradiol (E2)-filled Silastic implants for more 
than 18 months. Some of the treated animals develop grossly identifiable prostate 
tumors. 
Leav et al (1988) report that the simultaneous use of T and Ei would result in 
the abnormal development of prostate in Nb rats. Intact Nb rats would consistently 
develop prostatic dysplasia, a premalignant proliferation epithelial lesion, in 
dorsolateral prostatic lobe after 16 weeks' hormonal exposure. It is suggests that the 
dysplasia induced by this combined hormonal treatment may progress to carcinoma 
as long-term treatment of steroids (T+ E2) is known for the development of 
adenocarcinoma in dorsolateral prostate (Leav et al, 1988). 
Although testosterone (T) is carcinogenic in rat prostates as demonstrated by 
Noble (1982)，treatment with non-aromatizable dihydrotestosterone (DHT) alone 
fails to induce dysplasia (Leav et al, 1988). The failure to develop dysplasia with 
DHT whereas the development of prostate cancer under the combined treatment of 
T+E2 suggest that estrogenic action is involved in the abnormal and neoplastic 
growth of prostate and that estrogen can act as a causative factor in the genesis of 
prostatic dysplasia in Nb rats (Leav et al, 1988). 
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(c) Modified use of testosterone and 17P-estradioI filled Silastic implants in 
prostate cancer induction 
In order to induce a higher incidence rate and to shorten the induction period 
of prostate carcinogenesis, Wang and Wong (1998) develop a modified T+E2 
induction protocol based on the protocol originally developed by Leav et al (1988; 
1989). In this modified T+E2 induction protocol, the dosage of testosterone and 
estradiol are increased by using four Silastic tubings, of each with a larger internal 
diameter. Moreover, testosterone (T) is packed tightly to increase the dosage used. 
Over 90% of the Nb rats under this modified combined sex hormone treatment 
develop prostate cancer. Different degrees of prostate cancer ranging from highly 
differentiated to poorly differentiated type are observed (Wang & Wong, 1998). This 
protocol becomes a useful model for the study of prostate cancer as the period of 
induction is shortened, although a latency period of 6-9 months is needed. 
1.7.3 Sprague-Dawley rat model 
Dysplasia can also be developed in Sprague-Dawley (SD) rats when 
combined testosterone and estradiol treatment is used. It has been demonstrated that 
the frequency of developing dysplasia is as high as in Nb rats but the incidence of 
carcinoma is lower (Leav et al, 1989; Bosland et al, 1995). 
1.7.4 Wistar and F344 rat model 
Prostate cancer can be induced by hormone together with the use of chemical 




Testosterone (T) is used as a tumor promotor for rat prostate as long-term 
administration of T to rats enhances prostate carcinogenesis. In the Wistar rat model, 
rats are first put under a long-term administration of T and a single administration of 
a chemical organic carcinogen, N-methyl-N-nitrosourea (MNU) or N-
nitrosobis(oxopropyl)amine (BOP), is followed. In this model, a high incidence (66-
83%) of adenocarcinoma of the dorsolateral prostate is reported (Bosland, 2000). 
In the F344 rat model, the same hormonal treatment (testosterone, T) is 
applied but MNU or BOP is given during and after 10 repeated biweekly injection of 
another carcinogen, 3,2'-dimethyl-4-aminpbiphenol (DMAB), and proliferative 
lesions are induced in the ventral prostate (Bosland, 2000). 
1.8 Perinatal estrogen exposure and prostate development 
The imprinting or carcinogenic effects of perinatal exposure to estrogen in the 
prostate gland have been demonstrated in both rats and mice. These experiments 
were performed mostly between the 1970s and the 1980s (e.g. McLachlan et al 1975; 
Arai et al, 1983) as investigators were concerned about the effects of estrogens (or 
xenoestrogens) exposure due to environmental and agricultural contaminations on 
the development of reproductive system (丁oppar i et al, 1996). 
1.8.1 Prenatal estrogen exposure 
McLachlan and colleagues (1975) have performed a series of experiments to 
demonstrate the effects of prenatal estrogen exposure to the development of male 
reproductive system in mice. They treat the pregnant CD-I mice with DES on days 
9-16 of gestation. Glandular hyperplasia is developed in ventral prostate in prenatally 
DES-exposed male mice at old age. Estrogenic effects on other accessory sex glands, 
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like carcinoma in seminal vesicles, and epithelial lesions of squamous metaplasia, are 
also observed (Bosland, 2000). 
1.8.2 Neonatal estrogen exposure 
The effects of neonatal exposure to estrogen on the prostate have been 
demonstrated in the mice. When newborn HAN:NMRI mice are treated with DES 
(subcutaneous injection; 2 |Lig/pup/day) on days 1-3 after birth, an inhibition of 
prostatic growth is observed at 2 months of age. This growth inhibition on the 
prostate gland is permanent (Pylkkanen et al, 1996; Bosland, 2000). Besides, 
hyperplasia and dysplasia are developed in the prostate in aged mice. The estrogen 
hypersensitivity induced in the prostate gland is permanent, as demonstrated by the 
severity of dysplastic lesions increased after the treatment with DHT and estradiol 
(Pylkkanen et al, 1991). 
Arai et al (1983) treat Wistar rats with DES for the first 30 days after birth. 
Squamous cell carcinomas are induced in dorsolateral prostate and coagulating gland 
in 2 out of 11 castrated DES-exposed rats. Moreover, squamous metaplasia is 
observed in the coagulating gland in all these castrated DES-exposed rats. On the 
contrary, no hyperplasia or neoplasia is found in non-castrated DES-exposed rats, 
although squamous metaplasia is found in some of the treated animals. This suggests 
the carcinogenic effects of perinatal exposure of estrogen is involved in the 
neoplastic transformation in the prostatic cells. 
Both the prenatal and neonatal estrogen treatments clearly demonstrate that 
exposure of estrogen perinatally to rodents can be carcinogenic for prostate and the 
effect of estrogenization on the prostate gland is permanent. 
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Brief exposure of estrogen to rodents during early development of prostate 
gland alters the branching morphogenesis and cellular differentiation in a dose-
dependent manner (Prins & Birch, 1995). Estrogen-exposure during the critical 
period of prostate development would initially block the epithelial cells from 
entering a normal differentiation pathway, resulting in a permanent differentiation 
defect. Estrogen imprinting of prostate gland is believed to be mediated through the 
up-regulated levels of stromal estrogen receptor alpha (ERa), which in turn initiates 
alteration in steroid receptor expression in the developing prostate gland. 
Subsequently, prostatic development would be regulated by estrogen, rather than 
being dominated by androgen, in the estrogenized animals (Prins et al, 2001b) 
Neonatal imprinting or developmental estrogenization is found to be related 
with an increased incidence of prostatic premalignant and malignant lesions at 
elderly (Prins & Birch, 1997). Thus, neonatal estrogenization of rats is a useful 
model for the study of exogenous and endogenous estrogen in prostate disease later 
in life (Santti et al, 1994). 
1.9 Therapeutic use of synthetic estrogen 
1.9.1 Use of diethylstilbestrol in treating prostate cancer 
Diethylstilbestrol (DES), a synthetic estrogen, has biological properties that 
are similar to those of naturally occurring estrogens such as Ei and E2 (Dodds et al, 
1938). DES was first used by Charles Huggins to treat the advance prostate cancer 
patients in the early 1940s (Huggins & Hodges, 1941) as DES can act as a chemical 
castration agent by suppressing the release of gonadotropins by pituitary gland. DES 
can cause tumor regression by blocking the pituitary-testicular axis and the secretion 
of luteinizing hormone (LH) is then suppressed which in turn lowers the circulating 
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level of androgens produced by the testis. This inhibitory effect on gonadotropins 
forms the biological basis on the use of estrogen in treating prostate cancer patients. 
The use of DES is classic and effective in androgen deprivation therapy (ADP) 
(Malkowicz, 2001). However, there are some adverse side effects after DES 
treatment such as feminization, abnormal blood clotting, exacerbation of heart failure 
and other cardiovascular complications. As a result, the current use of DES in 
treating prostate cancer is very limited or terminated in the North America (Ahmed et 
al, 1998). 
1.9.2 Use of diethylstilbestrol during pregnancy 
DES was given to pregnant women between 1938 and 1971 because it was 
thought that DES would stimulate the release of estrogen and progesterone, restore 
hormone-balance and insure a healthy full pregnancy (Smith & Smith, 1949). It was 
believed that no side effect would be resulted when using DES during pregnancy. 
However, DES was not so effective in preventing miscarriage and premature births. 
On the contrary, the opposite was true (Brackbill & Berebdes, 1978). It is now 
known that both the women who took DES and their children are at risk of some 
health problems. Women who took DES may develop breast cancer at higher risk. 
DES is readily capable of crossing the placenta barrier and it can be conjugated and 
oxidatively metabolized in fetus (Metzler, 1981; Giusti et al, 1995). DES is also 
accumulated in fetal reproductive tract and exerts adverse effects there. DES-
daughters may have a risk of developing cancer of vagina or cervix and may have an 
increased incidence of structural changes in reproductive organs. DES sons may also 
develop reproductive tract anomalies. Other possible health effects of DES exposure 
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in DES sons include infertility and testicular cancer. It is also speculated that DES 
sons may develop prostatic hyperplasia and cancer (Giusti et al, 1995). 
Therefore, there is a potential risk in the exposure to excess exogeneous 
estrogen as many health problems may be derived from it. 
1.10 Estrogen contamination in food 
As exogenous estrogen may exert adverse effects on health and reproductive 
tract development and estrogen is considered to be involved in the development of 
prostate cancer, attention has been paid to the estrogen contamination in food. 
1.10.1 Estrogen in milk and dairy products 
According to Toppari et al (1996) and Hartmann et al (1998), the major 
sources of animal-derived estrogen are milk and dairy products such as cheese, ice-
cream and cold breakfast. 
High estrogen content can be found in milk as the milk human consumed may 
be obtained from heifers in the later half of pregnancy when estrogen levels are 
elevated (Gyawi & Pope, 1983). In Japan, the consumption of milk and dairy 
products has increased significantly after the World War II. Japanese children are 
given milk daily in school whereas pregnant women are also encouraged to consume 
milk and dairy products to meet the calcium needs during pregnancy (Ganmaa et al, 
2001). Under these situations, milk consumption has been increased sharply from 
1950 to 1997. Meanwhile, the incidence rate of prostate cancer is rising significantly 
during the same time (Hsing et al, 2000). This epidemiological survey suggests that 
the consumption of milk may be related to the increase in the incidence of prostate 
cancer in Japan. 
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Moreover, according to an epidemiological study performed in Northern Italy, 
there was a. significant increase of prostate cancer in frequent milk consumer, as 
compared with non-milk drinkers or occasional milk drinkers (La Vecchia et al, 
1991). This also suggests that milk, the major source of exogenous estrogen in food 
consumption, acts as a risk factor for prostate cancer (La Vecchia et al, 1991; 
Ganmaa et al, 2001). 
1.10.2 Estrogen in meat 
Another source of estrogen in food is meat. Hormones are used in livestock 
agriculture to increase the rate of weight gain and growth. Usually, pelleted hormone 
implants, such as estrogen, are injected under the skin on the back side of the ear. 
The US claims that the level of hormone in hormone-treated meat is low and 
insignificant to induce any health hazard as only a very small amount of hormone is 
used. However, based on an analysis carried out by the Europeans, the levels of 
naturally occurring hormones are increased in human after consuming the hormone-
treated meat as opposed to the non-treated meat (Barclay, 2001). 
Estrogen and its receptors have been speculated for a long time to play some 
roles in the normal and abnormal development of the prostate gland. This is based on 
the following fragmented evidences as shown in the literatures: (1) functional 
estrogen receptors are highly expressed in the prostate gland, (2) the direct effects of 
estrogen on the prostate gland, which may be mediated via estrogen receptors, can be 
demonstrated in animal models of BPH and prostate cancer, and the spectrum of 
pathologies including squamous metaplasia, dysplasia, carcinoma and altered growth 
of stromal tissues, can be induced by high levels of exogenous estrogens, (3) 
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perinatal exposure to estrogen in male rodents can lead to altered prostatic 
development and differentiation, (4) in vitro studies show that estrogen have direct 
effects in the growth of prostate cancer cells, and (5) estrogens and their metabolites 
are genotoxic as they can form DNA adducts and can induce mutation in cancers. 
However, the exact role of estrogen in the normal development and hormonal 
carcinogenesis of prostate gland is not clear. Based on this background, the estrogen 
carcinogenicity in the prostatic cells and prostate gland was investigated using both 
the in vivo and in vitro models of prostate cancer. 
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Figure 1.1 A graph showing the hypothesized relationship between estrogen and 
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Materials and methods 
Chapter 2. Materials and methods 
2.1 In vitro study of estrogen carcinogenicity in normal prostatic 
cell line 
For in vitro study of estrogen carcinogenicity and the effects of estrogen 
treatment on prostatic cells, a normal immortalized and non-tumorigenic rat prostatic 
cell line, NRP-152, was used. 
2.1.1 NRP-152 cell line 
The NRP-152 cell line was originally developed by and obtained from Dr. D. 
Danielpour of Case Western Reserve University, Cleveland, USA. NRP-152 was 
transformed from the dorsolateral prostate of N-methyl-N-nitrosourea (MNU)-treated 
Lobound-Wistar rats. Fibroblasts were removed by trypsin-EDTA and epithelial cells 
were allowed to grow. Among those remained attached after trypsinzation and 
passages, one colony of epithelial cells continued to grow and this line was termed as 
NRP-152 (Danielpour et al, 1994). For this cell line, no transfection or infection of an 
immortalizing gene was involved and it was considered as spontaneously 
immortalized. This cell line is non-tumorigenic and epithelial cell in original. These 
cells were grown in growth medium (RPMI 1640 [Gibco 31800] supplemented with 
10 mM HEPES, 5% fetal bovine serum [FBS], penicilli G [100,000 unit/L] and 
streptomycin sulfate [100,000 |ig/L]). 
2.1.2 In vitro estrogen treatment on NRP-152 cells 
(a) Dosage of estrogen treatment and cell growth 
In order to determine the optimal dosage of estrogen for cell treatment without 
a significant growth inhibitory effect, NRP-152 cells were treated in a series of 
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concentrations of IVP-estradiol (E2). Cells at density of 1 x lO* cells were seeded in 
each well of a 96-well plate. The seeded NRP-152 cells were allowed to grow in the 
growth medium for one day before estrogen treatment. The estrogen-containing 
growth medium was applied to the cells in the next day. E2 was dissolved in absolute 
ethanol at concentrations of 50 mM, 10 mM, 5 mM and 1 mM as the stock solutions. A 
graded concentration of E2 was then prepared in the growth medium (RPMI 1640 
supplemented with 10 mM HEPES, 5% FBS, penicilli G and streptomycin sulfate) as 
follows: 1 mM, 0.5 mM, 0.25 mM, 0.125 mM, 0.1 mM, 0.0625 mM, 0.03125 mM, 
0.015625 mM, 7.8125 |iM and 3.9 |iM of E2. Growth medium with equivalent volume 
of absolute alcohol (solvent of E2) added was also prepared. Cells grown in growth 
medium without estrogen were as control. Each concentration was prepared in 
quadruplets and repeated for two times. Cells were grown at a 37°C humidified 
incubator with 5% carbon dioxide (CO2) for two days, 
(b) Cell proliferation assay for dose selection for estrogen treatment 
The viability of cells grown at different estrogen concentration was determined 
using a colorimetric MTT assay (CellTiter 96® Aqueous Non-Radioactive Cell 
Proliferation Assay; Promega, USA), a cell proliferation assay. In brief, 100 |il PMS 
solution was first mixed with 20 叫 MTS solution. The mixed MTS/PMS solution was 
then diluted in 8 ml growth medium without FBS. Culture medium was removed from 
each well. 100 \i\ of the diluted MTS/PMS mixture was added to each well. MTS 
would be reduced biologically by the intrinsic dehydrogenase enzyme in the viable 
cells into a formazan product that was soluble in the medium. Color change was 
observed. The absorbance of the formazan at 490 nm was measured by an ELISA plate 
reader when color developed. The average reading at 490 nm at each estrogen 
concentration was calculated. The viability of the cells was determined by the ratio of 
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the absorbance reading under each different estrogen concentration to that of the 
control without estrogen treatment. The proliferation assay was performed for three 
times and the dosage at which there was a 0.5 viability of cells was selected for 
subsequent treatments for the cells. 
Based on the results of the proliferation assays, a concentration of 0.03 mM E2 
was selected for estrogen treatment. Cells at density of 2 x lO* were seeded onto a 35 
mm culture dish in growth medium for one day. In the next day, the cells were grown 
in fresh medium with 0.03 mM E2. The growth of the cells was monitored daily under 
an inverted microscope. E2-supplemented growth medium was replaced by normal 
growth medium for recovery when growth of the cells was severely inhibited. For 
controls, cells were grown in normal growth medium without the supplement with 
estrogen. 
2.1.3 Colony formation by soft agar assay 
An in vitro assay for anchorage independent growth, soft agar assay, was 
selected as a parametric indicator of cell transformation by estrogen (DiPaolo, 1983; 
Milo et al, 1981; Barrett & Ts，0’ 1978; Crane, 1999). When cells grew to 
approximately 90% confluency, both E2-treated and untreated parental cells were 
trypsinized for passage and soft agar assay (Russo et al, 2001; Calaf & Russo, 1993). 
(a) Preparation of agar layers for soft agar assay 
For agar assay, two layers of agar were prepared in the culture dishes. For the 
preparation of base agar, 1% Noble agar (Difco, USA) dissolved in autoclaved 
disdlled water was melted by heating in a microwave oven. Melted agar was kept at 
56°C in a water bath. A growth medium of 2X RPMI with 10% FBS was prepared and 
warmed at 37"C in a water bath. A 0.5% agar solution in IX RPMI with 5% FBS was 
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prepared by mixing 2X RPMI with 10% FBS and 1 % agar (1:1; v/v). The mixed 0.5% 
agar solution was added at 1 ml/well to a 6-well culture plate. The base agar (0.5%) 
was allowed to solidify at room temperature for about 30 minutes. Plates pre-coated 
with 0.5% base agar were ready for the setting of upper cell-agar layer or were stored 
at 4°C for later use. Cool wells with pre-coated base agar were pre-warmed at room 
temperature before use. 
The upper cell-agar layer was prepared as follows. Noble agar (Difco, USA) at 
concentration of 1.2% was dissolved in autoclaved distilled water and melted in a 
microwave oven. The melted agar was kept at 56°C in a water bath. The 1.2% agar 
solution and the pre-warmed 2X RPMI with 10% FBS were mixed in a ratio 1:1 (v/v). 
An agar solution at concentration of 0.6% with IX RPMI supplement with 5% FBS 
was prepared and kept at 37�C in a water bath. The E2-treated and untreated parental 
NRP-152 cells were trypsinized and counted with a hemacytometer under an inverted 
microscope. Cells at density of 1 x lO* cells/ml were resuspended in the growth 
medium. The suspended cells were mixed with 0.6% agar (1:1； v/v) to make a final 
density of 5,000 cells/ml in IX RPMI with 0.3% agar. Cell-agar suspension was plated 
at a volume of 2 ml/well (1 x lO"^  cells) onto wells pre-coated with 0.5% base agar. 
Cells were incubated at 37°C in a humidified incubator with 5% CO2 for about 4-6 
weeks. Fresh growth medium was added to the top of agar for feeding each week, 
(b) Colony selection 
The growth of the cells in agar was observed regularly for colony formation. 
Colonies formed in soft agar with size larger than 100 [im in diameter were picked up 
with a sterilized 1-ml syringe with 19G needle under a dissecting microscope. Each 
isolated colony was plated onto a well of a 12-well plate and allowed to grow and 
expand in normal growth medium and was kept at 3TC in an incubator. Cells 
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successfully grown and expanded from a single colony were considered as an 
E2-transformed clone. Four E2-transformed clones were isolated for subsequent 
studies. The isolated clones were grown and maintained in normal growth medium 
without the supplement with estrogen and passaged as the untreated parental NRP-152 
cells. 
2.1.4 Determination of growth parameters of the estrogen-transformed and 
untreated parental NRP-152 cells 
(a) Cell doubling time 
Cell doubling time was defined as the time required for doubling its number of 
cells during log phase of growth (Calaf & Russo，1993). To determine the doubling 
time，cells of the four isolated Ez-transformed clones and the untreated parental cells 
were seeded at density of 5,000 in each well of a 12-well culture plate. Cells were then 
grown at 37°C in a humidified incubator with 5% CO2. For every 24 hours after 
seeding, the cells were trypsinized and the number of cells was counted using a 
hemocytometer. The number of cells at each time point in logarithm was plotted and 
the doubling time was determined. The significance of the differences was determined 
by Student's t test (confident level = 0.95). 
(b) Colony-forming efficiency 
In order to study the colony efficiency, untreated parental NRP-152 cell line 
and the four isolated E2-transformed subclones of cells were grown in soft agar as 
described previously in section 2.1.3 (a). After growing in soft agar for 4-6 weeks, 
cells were fixed in 10% formaldehyde for 10 minutes and stained in 0.1 % crystal violet 
for another 5 minutes, followed by rinsing in tap water for destaining. The number of 
stained colonies per well was counted under a dissecting microscope. Colony 
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efficiency was determined as the number of colonies with size larger than 100 |im in 
diameter formed in the soft agar per total number of cells seeded (Russo et al, 2001). 
Colony efficiency was expressed as number of colony per 1 x lO^ cells. The 
significance of the differences was determined by Student's t test (confident level = 
0.95). 
2.1.5 Gene expression profiling in estrogen-transformed and untreated 
parental NRP-152 cells by cDNA microarray 
In order to assess and evaluate the profile of altered gene expression pattern in 
the E2-transformed NRP-152 cells, cDNA microarray was used. Two pathway-specific 
gene arrays, GEArray Q Series human androgen signaling and prostate cancer gene 
array and GEArray Q Series human DNA damage signaling pathways Gene Array 
(SuperArray Bioscience Corporation), were used in this study. In each microarray 
analysis, gene expressions of the Ea-transformed and untreated parental cells were 
compared. In this study, only one E2-transformed NRP-152 clone and the untreated 
parental NRP-152 were used, 
(a) RNA preparation 
Total RNA was extracted from both the E2-transformed and untreated parental 
NRP-152 cells using Trizol® reagent (GibcoBRL, Life Technologies Inc). When 90% 
confluency was reached, growth medium was removed and cells (parental and 
E2-transformed NRP-152 cells) were washed briefly with Hanks' solution. Trizol (1 
ml) was added to the culture dishes (60 mm). Cells dissolved in Trizol reagent were 
collected in 1.5 ml eppendorf tubes after being detached from the dish. In each tube, 
200 |il of chloroform was added. Samples were vortexed vigorously to extract RNA. 
Cell extracts were then centrifuged at 12,000 x g for 15 minutes at 4°C. Extracted RNA 
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located in the colorless upper aqueous layer was transferred to RNA-free 
micro-centrifuge tubes. RNA was precipitated by mixing with 500 }il isopropyl 
alcohol and was incubated for 10 minutes at room temperature. Samples were 
centrifuged at 12,000 x g for 10 minutes at 4�C. 70% alcohol was then added into the 
RNA pellet. Centrifugation at 75,000 x g for 5 minutes at 4 � C was followed. RNA 
pellet was washed with 70% ethanol and then air-dried. RNA was dissolved in 
RNase-free DEPC-treated water. The qualities of RNA samples were checked in an 
agarose gel before hybridization by examining the ratio of 28S and 18S ribosomal 
RNA. Only RNA samples producing two sharp bands, representing the 28S and the 
18S ribosomal RNA, with the 28S roughly two times more intense than the 18S, were 
used for microarray hybridization, 
(b) Pre-hybridization 
The pre-hybridization procedure was followed after RNA extraction. In brief, 
for each sample, 3 ml of GEAhyb Hybridization Solution was pre-warmed at 60°C to 
completely dissolve the solution. Sheared salmon sperm DNA was heat-denatured at 
10(fC for 5 minutes and then quickly chilled on ice. Heat-denatured salmon sperm 
DNA was added to the pre-warmed GEAhyb Hybridization Solution to a final 
concentration of 100 [ig DNA/ml. Mixed solution was kept at 60°C until use. A 
volume of 5 ml deionized water was added to the hybridization tube containing the 
GEArray™ Q Series membrane. Water was poured off after the membrane was 
completely wet. The array membrane was pre-hybridized in 2 ml prewarmed 
Hybridization solution with sperm DNA in the hybridization tube. Hybridization tube 
was vortexed gently for a few second and placed in a hybridization cylinder. The 
membrane in the hybridization cylinder was placed in a 60^C hybridization incubator 
(Robbins Scientific Model 1000) for an hour at 5-10 rpm with continuous agitation for 
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pre-hybridization of the array membrane. After pre-hybridization, pre-hybridization 
solution was discarded and was ready for hybridization with '^^P-labeled probes. 
(c) cDNA Probe synthesis 
cDNA probe labled with [a-'^'^P]dCTP by reverse transcription is described as 
follows. Annealing mix was prepared by mixing 5 |ig of total RNA with 3 |il of 
GEAprimer Mix (Buffer A). Final volume was adjusted to 10 |il with RNase-free 
water. Contents were mixed gently in sterile PGR tubes with a pipette followed by a 
brief centrifugation. Mixture was then heated at 70°C for 3 minutes and then cooled to 
42�C. Tubes with mixture were kept at 42�C for 2 minutes before the addition of the 
labeling mix. 
(d) Labeling mix and hybridization 
100 III of 5X GEAlabeling buffer (Buffer B) was prepared by mixing 50 |il of 
lOX RT buffer, 10 …of 0.1 M DTT and 40 |il dNTP mix (5mM dATP, 5mM dGTP, 
5mM dTTP, and 50 [iM dCTP). Mixed labeling buffer was then stored at -20°C until 
use. 10 IlII of master labeling mix was prepared for each RNA sample. For two samples, 
a 2.3X master labeling mix was made. 9.2 \i\ of 5X GEAlabeling buffer (Buffer B), 6.9 
III [a-33p]dCTP (10 |iCi/|il; Amershan Biosciences). 2.3 |il RNase inhibitor (Promega, 
USA), 2.3 |il M-MLV reverse transcriptase (Promega, USA) and 2.3 [i\ RNase-free 
water were mixed well and kept at 42°C for 2 minutes. 10 |il of labeling mix was 
transferred to each annealing reaction mix with gentle mixing. Mixtures of the 
annealing reaction and the labeling mix were incubated at 42�C for 25 minutes. 
Labeling reaction was stopped by adding 2 |il Stop Solution (Buffer C). "^^P-labeled 
cDNA probe was denatured by heating at 94�C for 5 minutes and chilling quickly on 
ice. Denatured ^^P-labeled cDNA probe was then mixed with 0.75 ml pre-warmed 
GEAhyb Hybridization Solution. Mixture was then added in the hybridization tubes 
3 2 
Materials and methods 
containing the pre-hybridized array. Hybridization was carried out with continuous 
agitation at 5-10 rpms at 60°C overnight. 
After hybridization, membranes were washed twice with wash solution 1 (2X 
SSC [20X SSC stock: 175.3 g NaCl, 88.2 g sodium citrate, adjusted to IL with 
distilled water], 1% SDS]) which was pre-warmed at 60°C. Washing was carried out in 
a hybridization incubator at 60°C for 15 minutes with agitation at 20-30 rpms. 
Membranes were further washed twice with wash solution 2 (O.IX SSC, 0.5% SDS). 5 
ml pre-warmed wash solution 2 was added to each tube followed a gentle vortex and 
incubation in hybridization oven at 60°C for 15 minutes with agitation at 20-30 rpms. 
(e) Image processing and data recording 
The hybridization signals of the "^V-labeled arrays were captured in a 
phosphoimager (Cyclone® Storage Phosphor Screen, Packard Bioscience Company, 
Downers Grove, Illinois, USA). Hybridization signals corresponding to the abundance 
of mRNA were detected by exposure of membranes for 30 minutes, 4 hours and 
overnight. Software, OptiQuant Acquistion and Analysis (Packard Instrument Co), 
was used for data recording. Digitalized image was extracted into a raw data table 
using a image-analysis software, FluroChem (Alpha Innotech Corp). Tetra-spot image 
of each gene in the array was then converted into digital data one by one. Final report 
data was produced using FluroChem (Alpha Innotech Corp). 
(f) Data Analysis 
A GEArrayAnalyzer software was used for data analysis. Data of digitalized 
image was normalized by designating the plasmid DNA (PUC18) as the negative 
control to remove the background from the experimental readings. The equation used 
was as follows: (the signal strength of gene A in experiment X - average of the 
negative control in experiment X). The signals were then compared between the 
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control sample and the Ei-transformed samples. 
2.1.6 Immunohistochemistry of cultured cells 
(a) Primary antibodies used for immunohistochemistry 
Based on the results from the cDNA microarrays, for the protein expression 
related to androgen signaling and prostate cancer gene, the following primary 
antibodies were used for immunohistochemistry. These included antibodies against 
tubulin-a Ab-2 (Clone DM1 A, a mouse monoclonal antibody raised against native 
chick brain microtubules; Santa Cruz Biotechnology, California, USA), Rap 1 (121，an 
affinity purified rabbit polyclonal antibody raised against a peptide mapping near the 
carboxy terminus of Rap lA of human origin; Santa Cruz Biotechnology, Inc, 
California, USA) and PTEN (FL-403, a rabbit polyclonal antibody raised against a 
recombinant protein corresponding to amino acids 1-403 representing full length 
PTEN [protein tyrosine phosphastase] of human origin; Santa Cruz Biotechnology, Inc, 
USA). For the study of the genomic stability and DNA repair, the expression of 
BRCA2 was also studied. The antibody used was BRCA2 (Ab-1, a rabbit polyclonal 
antibody raised against a synthetic 24-mer peptide, amino acid 1324-1347 
[YTAASRNSHNLEFDGSDSSKNDTV] for the human BRCA2 protein; Neomarkers, 
California, USA). 
Besides, the expressions of androgen receptor (AR) and estrogen receptors 
(ERa and ERp) were studied. One polyclonal antibody against androgen receptor 
(AR)，(PG-21, a affinity purified rabbit polyclonal antibody raised against a peptide 
corresponding to amino acids 1-21 of the human AR [MEVQLGL-
GRVYPRPPSKTYRG]; Upstate Biotechnology, USA) and two polyclonal antibodies 
against ERa (MC-20, an affinity-purified rabbit polyclonal antibody raised against a 
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peptide mapping at the carboxy terminus of the ERa of mouse origin; Santa Cruz 
Biotechnology, California, USA), and ERp (H-150, a rabbit polyclonal antibody 
raised against a recombinant protein corresponding to amino acids 1-150 mapping at 
the amino terminus ERp of human origin; Santa Cruz Biotechnology, California, USA) 
were used. Expression of superoxide dismutase (SOD-1) was also studied. Antibody 
against SOD-1 (FL-154; a rabbit polyclonal antibody raised against a recombinant 
protein corresponding to amino acid 1-154 representing full length of SOD-1 of 
human origin) was used, 
(b) Immunohistochemistry 
Both the untreated parental NRP-152 and the Ei-transformed cells were seeded 
on cover slides pre-coated with poly-L-lysine (0.01%) in a 24 well-plate. Cover slides 
with cells growing on them were first washed with PBS once when 80-90% 
confluency was reached. Cells were fixed in Carnoys，fixative for at least 30 minutes 
at room temperature. Before incubation with primary antibodies, fixative was removed 
and cells were washed with PBS for three times, of 5 minutes each. The primary 
antibodies, including antibodies against ERa, ERp, AR, tubulin-a, Rap 1’ PTEN, 
BRCA2，and SOD-1, were diluted in PBST (0.1 % BSA, 0.1 % Triton X-100 in PBS) in 
1:200 and the fixed cells were incubated with the primary antibodies in each well 
overnight at room temperature. After incubation with primary antibodies, cover slides 
were washed with PBS for three times to remove unbound antibodies. Slides with cells 
were then incubated with biotinylated secondary antibodies (biotin-Sp-conjugated 
goat anti-rabbit IgG or biotin-Sp-conjugated donkey anti-mouse IgG; Jackson 
ImmunoResearch Lab, USA) diluted in PBST (1:500) for an hour, followed by 
washing in PBS for three times. Cells were then incubated with a 
peroxidase-conjugated streptavidin (Jackson ImmunoResearch Lab, USA) diluted in 
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PBST (1:500) for an hour at room temperature. Color development was then 
performed. The expression of the proteins (except tubulin-a) was detected by 
conventional diaminobenzidine (DAB) reaction. Cells were washed with Tris buffered 
saline (TBS; 20 mM Tris HCl, 137 mM NaCl, pH 7.6) once. 0.5 mg/ml DAB in TBS 
was prepared and mixed with 0.015% H2O2. DAB was then added to the well for color 
development. Reaction was stopped by 0.1 M acetic buffer and then in tap water when 
brown color developed. For the detection of tubulin-a, peroxidase reaction was 
developed after washing in PBS. The glucose oxidase diaminobenzidine 
(DAB)-nickel intensifying procedure (Chan & Choi，1995) was performed. Cells were 
first washed with 0.1 M acetic buffer. Solution A (1.92 g nickel ammonium sulphate 
hexahydrate, 0.0192 g ammonium chloride and 0.096 g P-D-glucose dissolved in 24 
ml 0.2 M acetate buffer, pH 6) and solution B (0.024 g DAB dissolved in 24 ml 
distilled water) were mixed (1:1，V/v). 200 | L I 1 glucose oxidase (3.75 mg/ml) was added 
to the mixture. Cells were incubated in mixture A and B with glucose oxidase added. 
Peroxidase reaction was monitored and reaction was stopped by 0.1 M acetic buffer 
and then in tap water. After color development, cells were dehydrated in a graded 
series of ethanols, from 70%, 80%, 95% to absolute alcohol and cleared in xylene, 
followed by mounting with Permount®. The expressions of different protein markers 
by the untreated parental cells and E2-transformed cells were studied. 
2.1.7 Immunofluorescence on cultured cells 
The expression of cytoskeleton, tubulin-a, in NRP-152 cells was examined by 
immunofluorescence. The procedure of incubation with primary antibody (tubulin-a 
Ab-2; 1:200) and secondary antibody (bio-Sp-conjugated goat anti-mouse IgG; 1:200) 
diluted in PBST were as described as in section 2.1.6 (b). For immunosignal detection, 
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cells were incubated with FITC-conjugated streptavidin (Zymed Laboratory, Inc, 
California, USA) diluted in PBST (0.1% BSA, 0.5% Triton X-100 in PBS) in a ratio of 
1:200 for an hour, followed by three times of washing in PBS. Slides were then 
mounted with 50% glyerol in PBS (v/v). Fluorescence immuno-signals of tubulin-a in 
cells were examined under a confocal microscope (Bio Rad, MRC 1024). 
2.1.8 Electron microscopy of estrogen-transformed and untreated parental 
NRP-152 cells 
When approximately 90% confluency was reached, the four isolated 
E2-transformed NRP-152 cells and the parental NRP-152 cells growing in growth 
medium were fixed in 2% glutaraldhyde in 0.1 M acodylate buffer (pH 7.4) for 30-60 
minutes. After fixation, cells were washed with 0.1 M cacodylate buffer for three times 
for 15-30 minutes. Cells were post-fixed in a reduced osmium solution containing 1% 
osimiun tetraoxide and 1.5% potassium ferrocyanide for at least 30 minutes at room 
temperature, followed by washing in 0.1 M cacodylate buffer for three times (Kwong 
打 al, 1999). Post-fixed cells were kept overnight at 4 � C in 0.1 M cacodylate buffer 
with 4% sucrose. Cells were then dehydrated in 50%, 70%, 80% and 90% ethanol, of 
10 minutes each, and in absolute ethanol for three times, of 15 minutes each. 
Dehydrated cells were detached from the culture dish by brief washing with propylene 
oxide for 10 seconds. Detached cells were transferred to 1.5 ml micro-centrifuge tubes 
and pelleted by centrifugation with a bench-top centrifuge. Pelleted cells were washed 
with propylene oxide for two more times. Cells were infiltrated with propylene oxide 
and Epon 812 at ratio 1:1 and 1:2 for an hour each, finally in pure Epon 812 overnight. 
Polymerization of Epon 812 was performed at 60'^ C for 1-2 days. Sections were cut at 
thickness of 50-90 nm with an ultra-microtome (Leicer) and were collected on copper 
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grids for counter-staining with uranyl acetate and lead citrate. 
For section counter-staining, drops of Reynold's lead citrate solution were put 
on a clean sheet of parafilm in a petri-dish. Grids with sections were floated over the 
drops of lead citrate with sections facing downward and stained for 15 minutes at room 
temperature. Grids were then dipped with filter paper and washed in double-distilled 
water. The grids were stained in 4-10% uranyl acetate aqueous solution for 20 minutes. 
After being washed in water and air-dried, sections were examined with a transmission 
electron microscope (Hitachi H-71OOFA) at 70 kV. The ultrastructures of the untreated 
parental cells were compared with the cells from the Ea-transformed clones. 
2.1.9 l\imorigenicity in nude mice 
The tumorigenicity of Ez-transformed cells was examined in nude mice (Milo 
et al, 1981; Crane, 1999). Suspended cells were mixed with Matrigel for enhancing 
cell growth in nude mice. Matrigel (BD Falcon) was thawed at overnight while the 
eppendorfs and pipette tips were pre-cooled in ice before use. When confluency was 
reached，the Ez-transformed cells and untreated parental NRP-152 cells were washed 
briefly with Hanks' solution, trypsinized and counted. Cells were then resuspended at 
1 X 107 with 200 叫 Matrigel in a pre-cooled 1-ml syringe with 19G needle. The 
Matrigel-cell suspension was collected and allowed to solidify in the syringe at 3TC 
for about 30 minutes. Solidified Matrigel-cell suspension was injected subcutaneously 
into male nude mice which were supplemented with or without one 1-cm E2 tubing. 
For Ertubing transplantation, male nude mice were anaesthetized subcutaneously by 
0.1 ml 0.7% chloral hydrate. Solidified Matrigel-cell suspensions were injected 
subcutaneously at the back of the mice. Animals were caged and fed with chows and 
water ad libitum. 
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21.10 Protein expressions and Western blottings in estrogen transformed and 
untreated parental NRP-152 cells by Western Blotting 
(a) Protein extraction 
When nearly 90% confluency was reached, parental NRP-152 and the 
E2-transformed cells were lysed in 250 |il lysis buffer (20 mM PIPES, 0.25 M sucrose, 
1 mM EDTA, 1 mM EGTA, 1 mM monothioglycerol, 10 mM sodium fluoride, 0.5 
M M sodium orthoranadate, 1 mM P M S F , 2 |ag/ml aprotinin, 5 |liM leupeptin, 0 . 1 % 
SDS) in an ice bath for 15 minutes. Cells were then gently detached with a rubber 
policeman and sonicated with a sonicator (Bransonic) for an hour. Concentration of 
extracted protein was determined by bicochonimic acid protein assay (BCA protein 
assay; Pierce, USA) using bovine serum albumin (BSA) as standard. A series of 
graded BSA was prepared. The OD 650 nm was measured for different BSA 
concentrations and used to plot a standard curve. The concentration of the proteins in 
each sample was determined according to the standard curve. Proteins were then 
aliquoted into smaller volumes and kept at -20^： until gel electrophoresis. 
(b) Sodium dodecyl sulfate polyacylamide gel electrophoresis (SDS-PAGE) 
Based on the results from the BCA protein assay, same amount of protein 
samples were mixed with 1/5 of total volume of 2X sample buffer (100 mM/L Tris 
HCl，200 mM/L DDT, 4% SDS [w/v], 0.2% bromophenol blue [w/v] and 20% 
glycerol) and were adjusted to an equal total volume with lysis buffer. Extracted 
protein was denatured by heating at 95°C for 10 minutes. The denatured protein 
samples were separated by sodium dodecyl sulfate polyacylamide gel electrophoresis 
(SDS-PAGE) using a mini-gel apparatus (Bio-Rad, USA). Proteins were loaded at 20 . 
t^g per lane and separated at 100 V constant voltage about 1.5 hour. The apparent 
molecular sizes of the proteins were determined by referring to protein molecular 
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weight standard markers (Bio-Rad Laboratory). 
(c) Protein blotting 
After electrophoresis, gels were fixed in a transfer buffer (25 mM Tris, 192 
mM glycine, 10% methanol, pH 8.3) for about 30 minutes. Proteins were transferred 
from the gel onto polyvinylidene difluoride (PVDF) membrane (0.2 |im, Schleicher & 
Schuell, Germany) electrophoretically in transfer buffer at lOOV for about 1.5 hour in 
ice. The PVDF membrane was pretreated with methanol (one change), milli-Q water 
(two changes) and transfer buffer (one change) before blotting. 
After proteins were transferred onto the PVDF membrane, membrane was 
transferred to a blocking buffer (2.5% non-fat milk powder in PBS for 
immunoblotting). Membranes soaked in blocking buffer were shaken for an hour at 
room temperature over a rocking platform. Membranes were then washed in washing 
buffer (0.1% Tween-20 in PBS) for three times, of each for 10 minutes. After washing, 
membranes were incubated with various primary antibodies diluted in optimal 
dilutions in 2.5% milk-PBS (1:2000 for p-actin and 1:1000 for other antibodies) 
overnight at room temperature with gentle rocking. Before the incubation with 
secondary antibodies, membranes were washed in washing buffer (0.1 % Tween-20 in 
PBS) for three times to remove the unbound primary antibodies. Alkaline-phosphatase 
(AP) conjugated secondary antibody (AP-conjugate goat anti-mouse antibody and 
AP-conjugate goat anti-rabbit antibody; Zymed, USA), diluted in 2.5% milk-PBS 
(1:2000)，was applied to the membranes for an hour at room temperature with rocking, 
followed by three times of washing. 
(d) Signal detection 
The immuno-signal of the transblotted protein was detected by a colorimetric 
reaction. The reaction solution contained 45 |li1 of nitroblue tetrazolium (NBT, 75 
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mg/ml in dimethyformamide (DMFA) and 35 |li1 of 5-bromo-4-chloro-3-indolyl-
phosphate (BCIP, 50 mg/ml in 70% DMFA) dissolved in substrate buffer (100 mM 
Tris，100 mM NaCl and 50 mM MgCh) for color development. Colorimetric reaction 
was stopped by substrate buffer and then in distilled water. Membranes were dried 
with blotting paper. 
Antibodies used and staining conditions for Western blotting are summarized 
in Table 2.1. 
2.2 In vivo study of estrogen carcinogenicity in rat prostate gland 
For the present study, Noble (Nb) rats were used as the animal model of 
hormone-induced prostate cancer. This rat strain is susceptible to steroid hormones in 
the induction of hormone-dependent tumor, particularly in the prostate (Noble, 1982) 
and the mammary glands (Xie et al, 1999a; Xie et al, 1999b; Cheung et al, 2003). In 
the established protocols, premalignant and malignant epithelial lesions can be 
induced in the Nb rat prostate gland either by treatment with estrogen alone (Noble, 
1982) or by combined treatment with both androgen and estrogen (Leav et al, 1988; 
Xie etal, 2000; Li etal, 2001). In order to enhance the estrogen carcinogenicity in the 
Nb rat prostate, Nb rats were imprinted with estrogen perinatally and were further 
treated with a combination of estrogen and testosterone treatment at adulthood, based 
on the established protocols. 
2.2.1 Origin and supply of Noble rats 
Noble rat is an inbred strain originally developed by Dr. R. L. Noble of the 
Cancer Research Center in Vancouver. Noble selected the black-hooded rat colony and 
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further developed from the stock originally transformed from Dr. J. B. Collip's 
laboratory at McGill University in 1940s. Medical Research Council of Canada 
designated this strain as Noble (Nb) rat after evaluation on its genetics and degree of 
inbreeding contribution by Dr. Noble in 1997. It was thought that the ancestor of the 
Nb rat was the out-cross between the Long-Evan rats and Wistar rats. The offsprings 
were then randomly bred and only the blacked-hooded rats were selected for later 
experiments and used as breeders. 
Breeders of Nb rats were originally obtained from the Charles River Breeding 
Laboratories, Japan, in 1996. They were then bred in the Laboratory Animal Services 
Centre, the Chinese University of Hong Kong. 
2.2.2 Perinatal estrogen imprinting on male Noble rats with diethylestilbestrol 
(a) Preparation of diethylestibestrol (DES) for estrogen imprinting 
A synthetic estrogen, diethylstilbestrol (DES; Sigma Chemical Company, 
USA) was used for estrogen imprinting. DES was dissolved in corn oil in the 
concentration of 250 [Lg/m\ and 100 |Lig/ml for prenatal and neonatal estrogen 
treatment respectively. Solution was stirred until DES was completely dissolved. 
(b) Perinatal estrogen imprinting on Noble rats 
A sexually mature female Noble rat was placed with a male in a cage for 
mating. A total of 18 pairs were prepared. The presence of the post-copulatory vaginal 
plug was checked every morning in the following days after pairing. Females with 
vaginal plug found were considered to be mated and pregnant, and they were then 
separated from the males. The day when the plug was found was considered as 0.5 day 
of gestation. The gestation period of rat is about 21-23 days (Waynforth & Flecknell’ 
1992). 
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Fetuses or offsprings were treated with estrogen either prenatally or neonatally 
with DES. For prenatal estrogen treatment, a dosage of DES at 50 jig/kg body weight 
was applied to the pregnant female Noble rats at gestation day 18.5 and 20.5 (vaginal 
plug = 0.5 day) by subcutaneous injection at the back of the animals. The male 
newborns from these estrogen-treated female rats were selected for experiments and 
designated as preDES rats. For neonatal estrogen imprinting, the newborns were 
subcutaneously injected with DES (2 |ig DES/pup/day) on days 1 to 3 consecutively 
(DOB = day 1). Male rats under this treatment were designated as neoDES rats. For 
controls of prenatal and neonatal estrogen treatment, equivalent volume of corn oil 
was applied to the pregnant rats and male newborns, 
(c) Sexing of Noble rats 
At 3 weeks old, male littermates were separated from the females. Sexing was 
performed by lifting the tails and comparing the external genitalia among the 
littermates. Those having a larger genital papilla and greater anogenital distance were 
males. A maximum of five males from the same litter were placed in the same cage. 
2.2.3 Long-term hormonal treatment with sex steroids on male Noble rats at 
adulthood 
(a) Preparation of steroid-filled Silastic® tubings 
For further hormonal treatment, sex hormone-filled Silastic® tubings were 
implanted subcutaneously in the estrogen-imprinted male Nb rats at adulthood (12-13 
week olds). Silastic® laboratory tubings (Dow Cowling, Michigan, USA) with inner 
diameter 1.67 mm and outer diameter 3.18mm were cut into suitable lengths and filled 
with sex hormones. For testosterone-filled tubings (T; Fluka, USA), tubings with 
length of 2 cm were prepared while for estrogen-filled tubings (17p-estradiol [E2]; 
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Fluka, USA or DES; Sigma Chemical Company, USA), tubings with length of 1 cm 
were prepared. Both ends of the drug-filled tubings were sealed with Silastic® medical 
adhesive (Silicon type A; Dow Corning, USA) to prevent leakage. Tubings were 
soaked in 70% alcohol overnight to remove the residual powders of hormone adhered 
on the surface and to ensure the tubings were completely sealed. Tubings were further 
immersed in 0.05 M phosphate buffered saline (PBS) for one to two days before 
implantation. The tubings were stored at 4®C for later use after blotting dry with 
Kimwipes. 
(b) Surgical implantation of Silastic® tubings in male Noble rats 
When male Nb rats became sexually mature (12-13 weeks old), rats were 
anaesthetized by intraperitonal injection of 7% chloral hydrate (0.5 ml/100 g body 
weight) and implanted subcutaneously with steroid-filled tubings. The rats were 
treated and divided into three groups: (1) T+E2, (2) T+DES, and (3) control. The 
implantation site was made over the skin between scapulae. The skin was cut and a 
subcutaneous pocket was made with blunt forceps to accommodate the tubings after 
hair-shaving with an electric clipper and sterilizing with 70% alcohol. Two 
testosterone implants (2 x T) and one estrogen implant (1 x E2 or DES) were placed in 
the subcutaneous pocket and suture was followed. The suture site was then sprayed 
with a permeable wound dressing (Smith and Nephew Medical Limited, England). 
The animals were then housed in cages and fed on normal chows and drinking water 
ad libitum. The animals were treated for 6-9 months. Control animals were treated 
with equivalent number of empty tubings. A second implantation was performed at six 
months after the first implantation if treatments lasted for over 9 months. 
2.2.4 Morphological study of Noble rat prostates 
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(a) Histological preparation 
After hormonal treatment, Nb rats were sacrificed by injection of 7% chloral 
hydrate (0.5 ml/100 g body weight; i.p.). Prostate glands were dissected and fixed by 
immersion in freshly prepared Carney's solution (absolute methanol : chloroform : 
glacial acetic acid = 6 : 3 : 1; v/v/v) overnight. After fixation, the prostate-urethra 
complexes were cut horizontally and washed briefly in water. Tissues were dehydrated 
through a graded series of ethanols, cleared in xylene and embedded in paraffin. 
Paraffin sections were cut at thickness of 5 jim by a microtome and mounted on glass 
slides. 
(b) Routine histological staining 
The pathological alterations of estrogen imprinted Nb rat prostates were 
examined by routine hematoxylin and eosin (H & E) staining. Prostate sections were 
dewaxed in xylene and hydrated in a graded series of ethanols and then water. Sections 
were stained with hematoxylin, followed by bluing in Scott's tap water and staining in 
eosin. Excess eosin was removed by washing the sections in water. A quick 
dehydration of sections was performed in a graded series of ethanols and sections were 
cleared in xylene. Sections were mounted with Permount® and were examined with 
light microscope. 
2.2.5 Protein expressions by immunohistochemistry in estrogen-primed and 
hormone-treated Noble rat prostates 
(a) Primary antibodies used for immunohistochemistry 
For the study of protein expressions in the estrogen-primed and hormone 
treated Nb rat prostates, the following primary antibodies were used for 
immunohistochemistry. These primary antibodies included antibodies against 
4 5 
Materials and methods 
tubulin-a, Rap-1, PTEN, BRCA2, ERa, ERp, AR and SOD-1, as described in Section 
2.1.6 (a). 
(b) Immunohistochemistry 
The paraffin sections were dewaxed in xylene, hydrated in a decreasing series 
of ethanol and finally water. In order to block the endogenous peroxidase activity, 
sections were incubated in 0.35% hydrogen peroxidase (v/v) in absolute methanol for 
30 minutes. To retrieve and expose antigen binding sites, some sections were soaked in 
0.1 M Tris-base with 5% urea (pH 9.2) at 95�C for 20 minutes. After antigen retrieval 
by heating, sections were allowed to cool down to room temperature for about 15 
minutes. After rinsing with PBS, sections were incubated overnight with various 
primary antibodies diluted in optimal dilutions in a humid chamber at room 
temperature. The conditions for the incubation and dilutions of the primary antibodies 
are shown in Table 2.2. For negative control, primary antibody was omitted and 
sections were incubated with dilution buffer only. Unbound primary antibodies were 
removed by washing the sections with PBS for three times with gentle shaking. 
Diluted biotinylated secondary antibodies (1:200; biotin-Sp-conjugated goat 
anti-rabbit IgG and biotin-Sp-conjugated donkey anti-mouse IgG; Jackson 
ImmunoResearch Lab, USA) were used to recognize the primary antibodies bound in 
the sections and stain for an hour. After washing with PBS, sections were incubated 
with a diluted peroxidase-conjugated streptavidin (1:200; Jackson ImmunoResearch 
Lab, USA) for an hour in a humid chamber at room temperature. Sections were rinsed 
with PBS for three changes and then soaked in 0.1 M acetic buffer for 5 minutes. The 
immunoreactive sites were detected by a glucose oxidase-diaminobenzidine 
(DAB)-nickel intensifying procedure (Chan & Choi，1995). The solutions for this 
staining procedure were prepared as follows. Solution A (9.6 g nickel ammonium 
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sulphate hexahydrate, 0.096 g ammonium chloride and 0.48 g p-D-glucose dissolved 
in 120 ml 0.2 M acetate buffer, pH 6) and solution B (0.12 g DAB dissolved in 120 ml 
distilled water) were mixed before use (1:1, v/v). The sections were incubated in this 
mixed solution followed by adding of 1 ml glucose oxidase solution (3.75 mg/ml) for 
the generation of H2O2 and color development. Color development was monitored 
after 10 minutes of staining. DAB-peroxidase activity was stopped by incubating 
sections in 0.1 M acetate buffer followed by running in tap water. Sections were 
dehydrated in a graded series of alcohol, cleared with xylene and mounted with 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3. Results 
3.1 In vitro study 
3.1.1 Dose selection for estrogen treatment of NRP-152 cells from cell 
proliferation assay 
An MTT-based cell proliferation assay was performed in order to select an 
optimal concentration of estrogen for the cell treatments without significant 
inhibition of cell growth. The growth assay demonstrated that cell growth was in an 
inverse relationship with the concentration of E2 (Figure 3.1.1). After normalizing the 
data with the control readings, a cell viability of 50% was obtained when E2 
concentration was approximately 0.0625 mM. This suggested that at this 
concentration, E2 was high enough to exert the estrogenic effects on the NRP-152 
cells whereas at the same time allowed cell proliferation without a severe retardation 
on their growth. Based on this information, a slightly lower E2 concentration with a 
higher viability, 0.03 mM E2, was finally selected for the estrogen treatment of NRP-
152 cells in order to secure a successful growth and proliferation of cells under long-
term E2 treatment for the induction of transformation of cells. 
3.1.2 Colony formation in soft agar 
Soft agar assay was carried out for the study of cell transformation. After 
incubation for 6 weeks, the untreated parental NRP-152 cells developed no colony 
in the soft agar. Individual NRP-152 cells remained in the original form as they were 
seeded in the agar (Figure 3.1.2). The unsuccessful growth of the untreated parental 
NRP-152 cells in soft agar showed that the NRP-152 cells were anchorage 
dependent and thus they were not considered as transformed cells. 
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On the other hand, the E2-treated NRP-152 cells could form colonies in the 
soft agar. Cell aggregates developed from single E2-treated NRP-152 cell could be 
observed (Figure 3.1.3). This change in the ability to grow into a colony in the semi-
solid substratum after treating the cells with E2 suggested that E2-treated NRP-152 
were transformed or, at least to certain extent, that the E2-treated NRP-152 cells 
developed an ability of anchorage-independent growth in soft agar. Cells extended 
and grown from these colonies were considered as 17(3-estradiol (E2)-transformed 
NRP-152 cells. 
3.1.3 Morphology of NRP-152 cells and the estrogen-transformed clones 
(a) Morphology of parental NRP-152 cells 
The morphology of the parental immortalized prostatic epithelial NRP-152 
cells was studied. Parental NRP-152 cells were grown as a monolayer on the culture 
dish. In general, cells appeared oval in shape with a large centrally-located nucleus 
and a prominent nucleolus. Cell boundary was distinct and could be distinguished 
between the cells when confluency was reached. Cell-cell contact inhibition was 
apparent among the growing cells (Figures 3.1.4 - 3.1.5). 
(b) Morphology of the estrogen-transformed clones 
Morphological changes were observed in the Ei-transformed NRP-152 cells. 
E2-treated NRP-152 cells were isolated and expanded from four of the colonies 
formed in soft agar and they were considered as the Ei-transformed cells. The E r 
transformed cells appeared irregular in cell contour rather than oval as in the parental 
cells. When compared to the untreated parental NRP-152 cells, the cell boundary 
between the cells was unclear. Cell-cell contact inhibition appeared to be reduced or 
abolished among the growing cells (Figures 3.1.6 - 3.1.9). 
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3.1.4 Study of growth parameters 
(a) Doubling time 
The doubling time (DT) of the parental NRP-152 cells and the four estrogen-
transformed cells were determined and compared. It was found that the doubling 
time was increased in the four clones of cells, suggesting that the growth of the E2-
transformed cells was affected and slowed down by the estrogen treatment. The time 
required for the parental NRP-152 cells to double its cell number during the log 
phase was found to be 16.64 土 0.46 hours (hrs) while that of the four Ei-transformed 
cells clones were calculated to be 21.59 土 1.39 hrs, 23.39 土 2.34 hrs, 22.15 土 0.49 hrs 
and 23.77 土 2.87 hrs. The DT was significantly different (p < 0.05) in the E2-
transformed cells versus the untreated parental cells. The growth pattern of the E2-
transformed and untreated parental NRP-152 cells (in logarithmic scale) is presented 
in Figure 3.1.10. 
(b) Colony efficiency 
The efficiencies in forming colonies in soft agar were determined to evaluate 
the ability of the parental cells and the E2-transformed cells for anchorage 
independent growth. After growing for about 6 weeks, the number of colonies 
formed in the soft agar was counted. For the counting of colonies, a cell aggregate 
clonally developed from a single E2-transformed cell with size larger than 100 |im in 
diameter was considered and counted as a single colony (Russo et al, 2001). 
An increase in colony efficiency was found in the E2-transformed cells with 
NRP-152 clone no. 1 having the greatest colony efficiency. The colony efficiency of 
the untreated parental cells was 0.73 土 1.01 per 1 x cells. For the four E2-
transformed cells, the colony efficiencies was calculated as 7.35 土 1.93, 4.43 土 2.21， 
3.90土 2.92 and 6.91 土 1.91 per 1 x lO'^for clone no. 1，2, 3 and 4 respectively. The 
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colony-forming efficiencies of the E2-transformed cells were significantly different (p 
< 0.05) versus the untreated parental cells. 
The doubling time and the colony-forming efficiencies of the parental NRP-
152 and the E2-transformed clones of cells are summarized in Table 3.1. 
3.1.5 cDNA array analysis of differential gene expression 
From the results of microarray, different signal intensities of hybridization 
were observed for some genes expressed in the parental and E2-transformed NRP-
152 cells. Interested genes would be then selected for further verification by protein 
analysis if it showed a simultaneous difference in the signal intensity of the E〗-
transformed cells and an up-regulation or down-regulation of gene expression. In the 
first microarray (Androgen signaling and prostate cancer gene array), we analyzed 
the genes related to the prostate cancer. The selected genes for verification by protein 
expression included TUBA3 (a gene encoding tubulin-a which forms the tubulin and 
in turn the microtubule and a gene related to the switch of recurrent prostate cancer 
from androgen responsive to androgen independent), PTEN (a tumor suppressor gene 
encoding a putative protein tyrosine phosphatase and an androgen-independent 
prostate cancer-related gene) and RAPIA (a Ras-related tumor suppressor gene 
encoding 95% homologous 21 kDa proteins that share with Ras proteins a C-terminal 
sequence and associated with invasive prostate cancer) (Figure 3.1.11). In the second 
microarray (Human DNA damage signaling pathways gene array), we analyzed the 
genes involved in the DNA damage signaling. BRCA2 gene (a tumor suppressor 




TUBAS encodes a tubulin-a protein. Tubulin-a is one of the subunits of 
tubulin which is a component of microtubules. TUBAS gene can affect chromosome 
segregation in mitosis by regulating the formation of tubulin-a. A reduced gene 
expression was detected and the fold change in the E2-transformed NRP-152 cells 
was -10.09, suggesting it was significantly down-regulated by estrogen exposure. 
PTEN is a tumor suppressor gene and its protein product is a tyrosine 
phosphatase and tensin homolog (McMenamin et al, 1999). This homolog suggests 
that PTEN may function as a suppressor gene as it may suppress the growth of tumor 
cells by opposing the activity of protein tyrosine kinases. By microarray analysis, a 
decrease in expression was observed in the E2-transformed cells with a -2.358 fold 
change, when compared with the parental cells. 
RAPIA belongs to the Ras family (Stork, 2003). It is a /?a5-related tumor 
suppressor gene (Wani et al, 1997). Rap] A and Rap IB encode two highly 
homologous (95%) proteins that share with Ras protein a similar C-terminal 
sequence (Pizon et al, 1988). When compared with the radioactive signals between 
the parental and the E2-transformed cells, the expression of RAP J A was reduced after 
estrogen exposure. The fold change in the E2-transformed NRP-152 cells was found 
to be-1.633. 
BRCA2 is located in chromosome 13q (Dong, 2001). It is suggested to 
function as a tumor suppressor gene and its loss is related to breast cancer 
development (Rauh-Adelmann et al, 2000). BRCA2 mutation is also found to be 
associated with an increased risk of prostate cancer (Tulinius et al, 2002). Decreased 
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in radioactive signal was observed in the Ertransformed NRP-152 cells with a 
+ 5.18 fold change. 
The summary of the results of cDNA microarray is shown in Table 3.2. 
3.1.6 Immunohistochemistry of untreated parental and estrogen-transformed 
NRP-152 cells 
(a) Estrogen receptor a (ERa) 
In the parental NRP-152 cells, positive staining of ERa was seen in the nuclei 
of some of the cells (Figure 3.1.12). Most of the parental NRP-152 cells were 
unstained. 
The E2-transformed cells showed a similar labeling intensity of ERa in the 
nuclei (Figure 3.1.13). The majority of the cells were not stained as seen in the 
parental NRP-152 cells. 
(b) Estrogen receptor p (ERp) 
The untreated parental NRP-152 cells exhibited a strong nuclear staining 
(Figure 3.1.14), indicating the presence of ERp in the parental NRP-152 cells. 
In the E2-transformed NRP-152 cells, the immunolabeling of ERp was 
significantly reduced when compared with the untreated parental NRP-152 cells. 
Most of the cells were not stained with ERp antibody, illustrating a decreased level 
of ERp after estrogen treatment (Figure 3.1.15). 
(c) Androgen receptor (AR) 
A positive nuclear immunostaining of AR was detected in the untreated 
parental NRP-152 cells (Figure 3.1.16). 
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In the E2-transformed NRP-152 cells, the expression of AR was significantly 
reduced. Most E2-transformed cells were not labeled with AR antibody. A down-
regulation of AR was illustrated (Figure 3.1.17). 
(d) PTEN 
The protein expression of PTEN in the untreated parental NRP-152 cells was 
weak to moderate. The cells were weakly labeled at their cytoplasm (Figure 3.1.18). 
The overall change of the protein expression of PTEN in the E2-transformed 
NRP-152 cells was not very significant. In general, a slight decrease in the 
cytoplasmic expression of PTEN was observed in the E2-transformed cells (Figure 
3.1.19). 
(e) Rap 1 
Without being treated with E2, the parental NRP-152 cells expressed a 
moderate staining for Rap 1 (Figure 3.1.20). The positively stained cells exhibited a 
moderate cytoplasmic staining. 
After being treated with E2, Rap 1 protein was up-regulated in the E2-
transformed cells (Figure 3.1.21). Most of the E2-transformed cells were stained 
strongly with Rap 1 antibody. 
(f) BRCA2 
A high immunoreactivity of BRCA2 was observed in the untreated parental 
cells (Figure 3.1.22). The parental NRP-152 cells exhibited a strong nuclear staining, 
indicating that the BRCA2 was abundantly expressed in the nuclei of these prostatic 
epithelial cells. 
In the E2-transformed cells, the immunolabeling of the nuclei became 
weakened. A weak to moderate labeling of BRCA2 in the enlarged nuclei of the E2-
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treated cells was seen (Figure 3.1.23). A down-regulation of BRCA2 protein 
expression after estrogen treatment was observed. 
(g) Superxoidase dismutase (SOD-1) 
The untreated parental NRP-152 cells were positively stained with SOD-1 
antibody. The cells exhibited a moderate immunoreactivity of SOD-1 in the nuclei 
and the perinuclear cytoplasm (Figure 3.1.24). 
However, a loss of SOD-1 expression was detected in the NRP-152 cells 
transformed from estrogen treatment. The immunostaining of SOD-1 was 
significantly reduced. No nuclear or cytoplasmic staining was observed in the E2-
transformed cells (Figure 3.1.25). 
(h) Tubulin-a 
The immunostaining of tubulin-a was visualized by a nickel-DAB staining 
method in order to exhibit a better visualization of this cytoskeleton structure. The 
untreated parental cells expressed strong immunoreactivity. Tubulin-a was 
visualized as a network of filaments in the cytoplasm of the NRP-152 cells, leaving 
the nuclear region clear and unstained (Figure 3.1.26). 
After E2 treatment, a significant reduction of tubulin-a was seen in the E2-
transformed cells. The cytoplasmic labeling of tubulin-a was significantly reduced in 
the E2-transformed cells as compared with the untreated parental NRP-152 cells 
(Figure 3.1.27). 
The expression and localization of tubulin-a in the untreated parental NRP-
152 cells and E2-transformed cells were also examined by immunofluorescence. 
After immunofluorescent staining, tubulin-a was visualized as filament structures in 
5 7 
Results 
the cytoplasm. The stained microtubule filaments were concentrated at the periphery 
of the cells (Figure 3.1.28). 
The immunofluorescent study of tubulin-a in the E2-transformed cells was 
compared with the untreated parental NRP-152 cells. Similar to the 
immunoperoxidase staining, the immunofluorescent signal of tubulin-a was 
significantly reduced in the E2-transformed cells (Figure 3.1.29). 
3.1.7 Electron microscopy 
The ultrastructure of the untreated parental NRP-152 cells showed that the 
cells were well-differentiated. The cells contained a centrally located nucleus with 
one to two prominent nucleoli, occasionally surrounded by in dented nuclear 
envelope (Figure 3.1.30). The NRP-152 cells also contained the a moderate profile 
of rough endoplasmic reticulum with narrow lumens, a moderate amount of free 
ribosome, a moderate number of mitochondria which were usually located in the 
perinuclear region and a significant number of lysosomes. The bundles of 
microfilmaments were prominent in the perinuclear region. The cell also possessed 
some microvilli, which sometimes appeared as thick cytoplasm blebs in the region of 
cell body (Figures 3.1.31). 
It was found that one of the effects induced by the exposure of estrogen was 
the distortion of the ultrastructure of mitochondria. Mitochondrion had double 
membranes with a typical densely-packed cristae formed by the infoldings of the 
inner membrane and densely stained matrix. The ultrastructure of the E2-transformed 
cells was altered after the estrogen treatment. The mitochondria showed variable 
altered structures, including distorted inner membrane, a reduction in infoldings of 
the inner membrane and cristae in focal areas and an increase in electron-lucent 
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matrix in the lumen of the mitochondria (Figure 3.1.32). Alterations of the nuclear 
envelope were also seen in the E2-transformed NRP-152 cells. These included 
formation of myelinated membrane structure in the nucleus and disruption of nuclear 
envelope (Figure 3.1.33). An increase in the number of secondary lysosomes and 
residual bodies were observed in the E2-transformed cells (Figure 3.1.34). Besides, 
disorganized, rather than well organized, microtubules were observed in the E!-
transformed cells (Figure 3.1.35). In general, there was a reduction in the profile of 
rough endoplasmic reticulum, suggesting that the E2-transformed cells became less 
active in protein synthesis and differentiated as compared to the untreated parental 
NRP-152 cells. 
3.1.8 Tumorigenicity of NRP-152 cells and the estrogen-transformed clones 
The tumorigenicity of the four E2-transformed clones was examined in nude 
mice. Intact male nude mice were injected subcutaneously with Matrigel-cell 
suspension for each cell clone including parental NRP-152 and the four E2-
transformed clones of cells. The nude mice were supplemented with one estrogen 
(E2)-filled Silastic tubing. The injected cells were allowed to grow in the nude mice 
for up to 6 months. However, at the end of the experiment, none of the nude mice 
developed sign of tumor growth. 
3.1.9 Western blottings 
Expression of each protein was studied by Western blottings for at least 3 
times. Protein expression of the four E2-transformed clones relative to that of p-actin 
was shown in an arbitrary unit. Protein expression of the parental cells was adjusted 
as 1 for comparison. 
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The expression of various protein markers by Western blottings was 
normalized to the house-keeping gene product, P-actin, in the untreated parental and 
E2-tranformed NRP-152 cells. Equal amount of total proteins loaded for comparison 
could be indicated by SDS-PAGE, apart from the BCA assay. Expression of P-actin 
protein 42 kDa) protein was detected and equal intensity of expression was found 
in all samples. Therefore, the change of colorimetric signals for the tested proteins 
would be considered to be due to the result of alternation of protein expression in the 
cells but not of unequal amount of protein applied for each sample (Figure 3.1.36). 
(a) Estrogen receptor a (ERa) 
Three bands 67, 54 & 50 kDa) were obtained in the untreated parental and 
E2-transformed NRP-152 cells when expression of ERa protein was studied by 
Western blot analysis. A relatively low level of native ERa protein (~ 67 kDa) 
expression was detected in parental prostatic epithelial NRP-152 cells. For the native 
ERa protein expression in the four E2-transformed clones of cells, an overall higher 
signal intensity could be observed. The expressions of the putative ERa proteins 
54 kDa & 〜 5 0 kDa) were slightly lower in the E2-transformed cells than the 
untreated parental NRP-152 cells, especially in E2-transformed clone no. 3 (Figure 
3.1.37 [a] - 3.1.37 [d]). It might suggest that estrogen may up-regulate the native 
ERa expression in the prostatic cells in vitro. 
(b) Estrogen receptor p (ERp) 
The presence of ERp protein 60 kDa) was detected in both untreated 
parental NRP-152 cells and its E2-transformed clones. A high expression level of 
ERp protein was shown in the untreated parental NRP-152 cells. However, a marked 
decrease in ERp protein expression was observed in the protein samples obtained 
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from the four E2-transformed clones of cells. The highly expressed ERp protein in 
the parental NRP-152 cells was down-regulated after E2 treatment (Figure 3.1.38 [a] 
-3.1.38 [b]). 
(c) Androgen receptor (AR) 
The expression of AR protein was visualized as a band of about 110 kDa in 
both the untreated parental and Ea-transformed NRP-152 cells by Western blotting. 
A moderate expression of AR protein was observed in the untreated parental NRP-
152 cells. However a decrease in AR expression were found in the four E2-
transformed clones (Figure 3.1.39 [a] - 3.1.39 [b]). 
(d) Tubulin-a 
By Western blotting analysis, expression of tubulin-a protein was detected as 
a band at about 57 kDa in SDS-PAGE. Although a marked decrease of tubulin-a 
expression was detected by immunohistochemistry, the decrease in tubulin-a 
expression was unexpectedly not of a great significance in the E2-transformed cells 
by Western blot (Figure 3.1.40 [a] -3.1.40 [b]). 
(e) PTEN 
By Western blotting, PTEN was detected as a band of about 60 kDa. A high 
expression of PTEN protein was detected in the protein sample obtained from the 
parental cells, suggesting an abundant amount of PTEN protein in parental NRP-152 
cells. A reduced expression of PTEN protein was seen in the NRP-152 cells 
transformed by E2 treatment (Figure 3.1.41 [a]-3.1.41 [b]). 
(f) Rap 1 
Rap 1 protein was expressed as a band at about 22 kDa in the protein samples 
of the untreated parental and E2-transformed cells. A moderate expression of Rap 1 
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was seen in the parental NRP-152. An elevated colorimetric signal was observed in 
the E2-transformed clones of cells, except E2-transformed clone no. 3, showing an 
up-regulation in Rap 1 expression in the prostatic epithelial NRP-152 cells after E2 
treatment (Figure 3.1.42 [a] - 3.1.42 [b]). 
(g) BRCA2 
By Western blotting, BRCA2 was detected as a band of about 380 kDa in 
both the untreated parental and Ei-transformed prostatic epithelial NRP-152 cells. 
Expression of BRCA2 protein in the parental cells was moderate. Various 
expressions of BRCA2 were observed in the E2-transformed cells. For E2-
transformed clone no. 1 and 2，a higher BRCA2 expression was observed. However, 
a reduced intensity was seen in the Ei-transformed clones no. 3 and 4’ suggesting the 
expression of this protein in these two Ea-transformed clones of NRP-152 cells was 
down-regulated by estrogen treatment (Figure 3.1.43 [a] - 3.1.43 [b]). 
(h) SOD-1 
By Western blotting, SOD-1 was detected as a band of about 20 kDa in the 
SDS-PAGE. A lower intensity of SOD-1 expression was observed in the E2-
transformed clones no. 2 and 3 while its expression in the clone no. 1 and 4 was 
increased (Figure 3.1.44 [a] - 3.1.44 [b]). 
The summary of the results of immunohistochemistry and Western blottings 
in parental and E2-transformed NRP-152 cells is shown in Table 3.3. 
3.2 In vivo study 




All the male Noble (Nb) rats in the control groups (treated with corn oil and 
empty hormonal tubings) survived upon the end of the experiment. For the prenatal 
estrogen imprinted rats (preDES rats), seven out of nine male rats further treated with 
T+E2 survived until being sacrificed while five out of six treated with T+DES 
survived. Among eight neonatally estrogen treated male rats (neoDES rats), six 
survived after the combined T+E2 treatment. Among the three neoDES rats treated 
with T+DES, only one was left at the end. 
Nb rats were sacrificed after prolonged combined treatment of either T+ E2 or 
T+DES. Inflamed prostates (Figure 3.2.1) and gross prostate tumors (Figure 3.2.2) 
were observed in estrogen imprinted and hormonal treated rat prostates. 
3.2.2 Histological studies of Noble rat prostates 
The morphology of prostates of the untreated control rats and those of the 
hormonal treated were examined histologically, 
(a) Histology of prostate in the control Nb rats 
Rat prostate gland is composed of three distinct lobes and is tubuloaveloar in 
structure. The normal prostate consists of a large number of acini which are lined by 
a pseudostratified or simple columnar (or cuboidal) epithelium. The three prostatic 
lobes and the acini are surrounded by a thin layer of smooth muscle layer. 
In the control ventral prostate (VP), the acini were lined by a layer of 
basophilic columnar cells. Prominent nuclei were located at the basal sides of the 
cells. The glandular acini in VP were cystic within lumens filled with glandular 
secretions but its epithelial foldings were few and widely separated. The acini were 




Similar to VP, the lateral prostate (LP) was also consisted of acini. However, 
when compared with VP, the acini in LP appeared smaller and the lining epithelium 
was highly folded. Epithelial cells lining the acini were low columnar or cuboidal in 
shape and stained less basophilic. The acini contained less granular secretion (Figure 
3.2.4). 
As compared to LP, dorsal prostate (DP) contained larger acini. The acini 
were lined by a pseudostratified or simple columnar epithelium. The epithelial cells 
were stained eosinophilic and secreted in an apocrine secretory mode. The most 
distinct feature of DP was that acini contained homogenous eosinophilic secretions 
(Figure 3.2.5). 
(b) Histology of prostates in the estrogen-imprinted and hormone-treated 
male Noble rats 
In the estrogen-imprinted and hormone-treated ventral prostate, low-graded 
prostatic intraepithelial neoplasm (PIN) was developed. PEN was developed in the 
luminal epithelium of VP. Epithelia proliferated at the alveloar lining but lumen was 
not obliterated. The proliferated epithelium was about 2-3 cell-layers thick 
meanwhile normal architecture of the acini was preserved (Figure 3.2.6). 
PIN was induced in the Nb rat LP after perinatal estrogenization and long-
term hormone treatment. PIN of flat and tufting patterns was detected at the acini and 
micropapillary pattern of high-graded PIN was also seen. Micropapillary pattern of 
PIN was characterized by the presence of numerous finger-like projections of 
epithelial cells which were protruding into the lumen of acini. Besides, acini with 
low-graded PIN lesions were observed in LP. Epithelial cells were proliferated along 
the lumen. Complex intra-acini epithelia proliferation with lumen formed by the 
fusion of projection papillae was observed at focal area (Figure 3.2.7). 
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In the DP of the estrogen-imprinted and hormone treated Nb rats, low-graded 
PIN was also observed as in LP and VP. Flat and tufting pattern was observed along 
the lumen where there was a proliferation of epithelial cells. Epithelial cells were 
proliferated and appeared as 2-3 cell-layers thick, lining the lumen of acini. Lesions 
were appeared as stratification of epithelial cells. A flat contour of luminal surface 
was seen. Some cystic spaces were formed by the fusion of intra-acinar epithelial 
cells which grew into the lumen (Figure 3.2.8). 
3.2.3 Immunohistochemistry of the hormone-treated and control Noble rat 
prostates 
(a) Estrogen receptor a (ERa) 
The expression of ERa protein was detected in control Nb rat prostates. In the 
control VP, a moderate immunohistochemical staining of ERa was mostly seen in 
the nuclei of stromal cells surrounding the acini (Figure 3.2.9). Immunoreactivity of 
ERa was also seen in the nuclei of the epithelial cells lining the acini in the LP and 
DP of the control rats. A moderate to strong ERa staining was detected in the nuclei 
of the epithelial cells (Figure 3.2.10). 
A positive immunoreactivity of ERa was also detected in the stromal smooth 
muscle cells lying underneath the acini of the VP in the estrogen-imprinted and 
hormone-treated rats. When comparing this staining pattern with the control, the 
immunoreactivity of ERa appeared to be increased in the smooth muscle cells after 
estrogen exposure. An increase in blood vessel formation was also observed after 
estrogen treatment (Figure 3.2.11). In the LP of the estrogen-imprinted and hormone-
treated rats, a strong immunoreactivity of ERa was observed in the nuclei of the 
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proliferated smooth muscle cells in the stroma (Figure 3.2.12). Hyperplasia was also 
resulted after estrogen treatment. A proliferation of epithelial cells was detected 
along the lumen of acini. Disrupted stromal cell layer was observed (Figure 3.2.13). 
The expression of ERa was also localized in the nuclei of the smooth muscle cells in 
LP (Figures 3.2.13-3.2.14). 
(b) Estrogen receptor P (ERp) 
Immunoreactivity of ERp was detected in the control Nb rat prostates. In the 
VP, an intense nuclear immunostaining was observed in the epithelial cells (Figure 
3.2.15). In the control LP, immunoreactivity of ERp was also highly expressed in the 
nuclei of the epithelial cells (Figure 3.2.16). A positive strong staining of ERp was 
observed in DP. 
An overall decrease in ERp immunoreactivity was observed in all the three 
prostatic lobes after perinatal estrogen treatment and further hormone treatment. In 
the VP, hyperplasia was induced after the estrogen-imprinting and long-term 
hormone treatment. Glandular enlargement and increased infoldings were observed. 
Positive ERp immunoreactivity was observed in the nuclei of some of the prostatic 
epithelial cells lining the acini where premalignant prostatic lesion developed while 
some of the cells showed a decreased expression of ERp (Figure 3.2.17). ERp 
expression was severely lost in the nuclei of the epithelial cells of the LP when 
adenocarcinoma developed. A weak ERp labeling was shown at the nuclei of the 
epithelium of the LP (Figure 3.2.18). In LP, for those epithelial cells expressing 
positive immunosignals of ERp, the level of immunostaining was not as strong as in 
the control LP. In addition, it was noted that positive labeling of some ERp was 
localized at the bottom of the proliferating cell layer which developed as high-graded 
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PIN lesion with micropapillary pattern (Figure 3.2.19). In the DP, proliferation of 
epithelial cells along the lumen of acini was seen in the estrogen-imprinted and 
hormone-treated rats and epithelial height was increased. Immunohistochemistry of 
ERP exhibited a moderate nuclear expression in the epithelial cells lining the lumen 
and the proliferated epithelium outgrowth (Figure 3.2.20). 
(c) Androgen receptor (AR) 
The expression of AR is known to be correlated with the histological grade of 
prostate in an inverse manner. A significant strong AR expression was detected in 
the nuclei of the control prostatic epithelial cells of the three lobes by 
immnuohistochemistry. The nuclear expression of AR was intense and strong in the 
epithelium of the VP (Figure 3.2.21). This highly expressed AR immunostaining was 
also observed in the LP and DP (Figure 3.2.22). 
After perinatal estrogen exposure and long-term combined hormone 
treatment, the expression of AR was generally decreased in the nuclei of the 
epithelial cells in all the three prostatic lobes. In general, a low to moderate 
immunoreactivity of AR was detected in the nuclei of epithelial cells of VP where 
low-graded PIN (Figure 3.2.23) and hypertrophy was developed by the proliferation 
of epithelial cells long the luminal walls (Figure 3.2.24). The nuclear 
immunoreactivity of AR was almost lost in the epithelium of the lumen in LP. The 
nuclei of the luminal dysplastic epithelial cells were weakly stained or lost (Figure 
3.2.25). In DP, a low to moderate expression of AR was detected. A moderate 
positive nuclear staining was observed in the normal epithelial lining whereas 




Tubulin-a is a subunit of tubulin which in turns forms the microtubules. 
Large aggregates concentrating at the cell periphery was shown when the epithelial 
cells were immunostained with tubulin-a antibody. By immunohistochemistry, 
tubulin-a was highly expressed in the cytoplasm of the epithelial cells in LP, VP and 
DP of the control rat prostates. Strong expression of tubulin-a was localized in the 
apical cytoplasm of the prostatic epithelial cells lining the lumen. This suggested a 
high abundance of this protein in the prostatic epithelial cells in the three prostate 
lobes of the control rats (Figures 3.2.27 - 3.2.28). 
An overall decrease of cytoplasmic tubulin-a staining was observed in the 
prostate gland after estrogen-imprinting and further hormone treatment. The strong 
immunostaining pattern of tubulin-a was greatly lost in the VP where low-graded 
PIN of micropapillary pattern developed. The cytoplasm of the luminal dysplastic 
epithelial cells was unstained (Figure 3.2.29). A low to moderate expression of 
tubulin-a was seen in the epithelial cells in PIN lesions in LP. Immunoreactivity of 
tubulin-a in the luminal dysplastic epithelial cells were weakly stained or unstained. 
However, for those epithelial cells located basal ly in PIN and the normal lumen, a 
positive cytoplasmic staining of moderate intensity was observed (Figure 3.2.30 -
3.2.31). An obvious reduction of tubulin-a expression was seen in the cytoplasm of 
the epithelial cells in adenocarcinoma lesion induced in LP. Cytoplasm of the tumor 
cells showed a weak to moderate labeling while large adenocarcinoma cells which 
formed cords were positively stained at a moderate level (Figure 3.2.32). In DP, a 




In the control VP, LP and DP, a moderate immunostaining intensity was seen 
in the cytoplasm of the luminal epithelial cells, indicating the presence of this 
suppressor gene product for abnormal growth suppression in control prostatic 
epithelial cells (Figures 3.2.33 - 3.2.34). 
After estrogen-imprinting and hormone treatment, a loss of PTEN expression 
was seen in the cytoplasm of the epithelial cells lining the acini in VP where low-
graded PIN of tufting pattern developed. The expression of PTEN in epithelial cells 
of the individual mounds of proliferating epithelial cells was barely visible (Figure 
3.2.35). A weak immunoreactivity of PTEN in the LP was also observed after 
estrogen and hormone treatment. In the acinus with low-graded PIN formation, 
epithelial cells showed a loss of immunosignal (Figure 3.2.36). In the high-graded 
PIN lesion with micropapillary patterns developed in LP, the luminal epithelial cells 
were negatively labeled. A moderate cytoplasmic staining of PTEN was seen in the 
epithelial cells of the acini where no lesion developed (Figure 3.2.37). In the DP, the 
cytoplasmic expression of PTEN in the epithelial cells lining the acinus was 
significantly down-regulated. A cribiform pattern of low-graded PIN, as 
characterized by the intra-acinar epithelial proliferation, was induced in the DP. 
Secondary lumina were formed by the fusion of projecting papillae. The proliferated 
dysplastic epithelial cells showed a negative PTEN labeling (Figure 3.2.38). 
(f) Rap 1 
A low to moderate staining intensity of Rap 1 was examined in the cytoplasm 
of luminal epithelial cells in VP of the control rats by immunohistochemistry (Figure 




Abnormal premalignant lesions of hyperplasia and low-graded PIN of flat 
pattern and tufting were observed in the estrogen-imprinted and hormone-treated VP. 
In the lumen developing dysplastic hyperplasia, a moderate to strong signal of Rap 1 
was observed in the cytoplasm of the epithelial cells. In low-graded PIN lesions, 
epithelial cells also showed a moderate expression of Rap 1，as shown by the 
enhanced immunoreactivity in the cytoplasm of the dysplastic epithelial cells. On the 
contrary, decreased expression of Rap 1 was observed in prostatic cells developing 
higher grade of prostate lesions and cells exhibiting intra-acinar epithelial growth. 
Stromal smooth muscle cells proliferating in the lumen of the acini in VP was also 
seen (Figure 3.2.40). In the DP of the estrogen-imprinted and hormone-treated rats, 
the epithelial cells showed a decreased cytoplasmic Rap 1 expression in the 
proliferated intra-acinar epithelial cells (Figure 3.2.41). 
(g) BRCA2 
In VP of the control rats, immunoreactivity of BRCA2 was highly expressed 
as a strong nuclear staining was observed in the luminal epithelial cells (Figure 
3.2.42). BRCA2 was also clearly and strongly expressed in the nuclei of the 
epithelial cells of the control LP and DP (Figure 3.2.43). 
In the VP of the estrogen-imprinted and hormone-treated rat, non-lesion acini 
as well as low-graded PIN were observed (Figure 3.2.44). A positive nuclear 
immunostaining pattern of BRCA2 could be observed in the epithelium of acini 
without lesion development. On the contrary, a significant reduced expression of 
BRCA2 was detected in the nuclei of the luminal epithelial cells of low-graded PIN. 
Acini with PIN of flat and tufting pattern were observed in LP. The luminal 
dysplastic epithelial cells were mostly weakly labeled in the nuclei (Figure 3.2.45). 
PIN of the micropapillary pattern was developed in the acini after estrogen 
7 0 
Results 
imprinting and hormone treatment. A loss of BRCA2 expression was seen in the 
luminal epithelial cells (Figure 3.2.46). For the immunostaining of BRCA2 in DP 
after estrogen imprinting and hormone treatment, positive staining pattern was 
confined to the nuclei of the epithelial cells where no lesion developed. In the acini 
with PIN of tufting pattern, the nuclear BRCA2 expression was lost in the luminal 
epithelial cells (Figure 3.2.47) 
(h) Superoxidase dismutase-1 (SOD-1) 
Superoxidase-dismutase (SOD-1) is responsible for removing reactive 
oxygen species (ROS) in the cells. Its expression can be found in both nucleus and 
cytoplasm. 
In the control VP, a weak or negative immunostaining of SOD-1 was seen in 
the nuclei of epithelial cells. A weak cytoplasmic immunostaining of SOD-1 was 
also observed in LP. In the control DP, SOD-1 was expressed weakly as in LP. The 
expression of SOD-1 was localized to the apical cytoplasm of epithelial cells (Figure 
3.2.48). 
Different degrees of premalignant and malignant lesions were induced in the 
Nb rat prostates after estrogen-imprinting and hormone treatment (Figures 3.2.49 -
3.2.50). A clear and intense SOD-1 immunoreactivity was detected in the nuclei of 
the epithelial cells of the acini which appeared normal in structure. In acini with PIN 
lesion or invading lesion, the epithelial cells were weakly stained in their nuclei, as 
compared with the unaffected acini (Figure 3.2.49). In the advanced lesion of 
carcinoma in situ developed in the LP, a loss of nuclear immunostaining of SOD-1 in 
the nuclei of the epithelia cells was seen (Figure 3.2.50). The different expression 
pattern of SOD-1 in acini after hormone treatment might suggest that the relative 
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expression levels of SOD-1 might be related to the development of premalignant and 
malignant lesions in the prostate. 




The viability of NRP-152 in response to different estrogen concentrations. 50% 
viability is obtained at 0.0625 mM E2 concentration (green bar). A slightly lower E2 
concentration with a higher viability, 0.03 mM, is selected for estrogen treatment of 
NRP-152 cells to secure a successful growth and proliferation of cells under long 
































































































































































The growth of parental NRP-152 cells in soft agar. Cells appear as single cells. No 
colony is formed (x 100). 
Figure 3.1.3 
The growth of an Ea-transformed NRP-152 cells in soft agar. A colony of size 〜100 
|im in diameter is observed (x 200). 
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Figures 3.1.4 - 3.1.5 
The morphology of untreated parental NRP-152 cells. A monolayer of oval-shaped 
cells is grown (Fig. 3.1.4, x 100). Centrally located nuclei and distinct cell boundary 
are observed (Fig. 3.1.5，x 200). 
Figures 3.1.6 - 3.1.9 
The morphology of the four clones of E2-transformed NRP-152 cells. Irregular cell 
shape and unclear cell boundaries are seen (x 200). 
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The growth of the parental NRP-152 cells and the four E2-transformed cells (in 





























































































































































































































The gene expression of the untreated parental NRP-152 cells and the E2-transformed 
NRP-152 cells in the androgen signaling and prostate cancer gene array. Circled are 



























































































































The expression of ERa in the parental NRP-152 cells (Fig. 3.1.12; x 400) and E2-
transformed NRP-152 cells (Fig. 3.1.13; x 400) by immunohistochemisry. Similar 
nuclear ERa expression is observed in the E2-transformed cells. 
Figures 3.1.14-3.1.15 
The expression of ERP in the parental NRP-152 cells (Fig. 3.1.14, x 400) and E2-
transformed NRP-152 cells (Fig. 3.1.15, x 400) by immunohistochemisry. Lost in 
nuclear ERp expression is observed in the majority of the Ei-transformed cells. 
Figures 3.1.16-3.1.17 
The expression of AR in the parental NRP-152 cells (Fig. 3.1.16, x 400) and Ej-
transformed NRP-152 cells (Fig. 3.1.17, x 400) by immunohistochemisry. Down-
regulated nuclear expression is observed in the E2-transformed cells. 
Figures 3.1.18-3.1.19 
The expression of PTEN in the parental NRP-152 cells (Fig. 3.1.18, x 400) and E2-
transformed NRP-152 cells (Fig. 3.1.19, x 400) by immunohistochemisry. A 
moderate immunostaining is observed in the control cells while a further lost in 
cytoplasmic expression is observed in the E2-transformed cells. 
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The immunostaining of Rap 1 in the parental NRP-152 cells (Fig. 3.1.20’ x 400) and 
of El-transformed NRP-152 cells (Fig. 3.1.21, x 400). An increase in cytoplasmic 
Rap 1 expression is illustrated in the E2-transformed cells. 
Figures 3.1.22-3.1.23 
BRCA2 expression in the parental NRP-152 cells (Fig. 3.1.22, x 400) and E2-
transformed NRP-152 cells (Fig. 3.1.23, x 400) by immunohistochemisry. A 
decreased nuclear expression is observed in the Ei-transformed cells. 
Figures 3.1.24-3.1.25 
The expression of SOD-1 in the parental NRP-152 cells (Fig. 3.1.24, x 400) and E2-
transformed NRP-152 cells (Fig. 3.1.25, x 400) by immunohistochemisry. A reduced 
nuclear and cytoplasmic expression is shown in the E2-transformed cells. 
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Tubulin-a expression in the parental NRP-152 cells (Fig. 3.1.26, x 400) and E2-
transformed NRP-152 cells (Fig. 3.1.27’ x 400) by immunohistochemisry. 
Significant decrease of cytoplasmic tubulin-a expression is demonstrated in the E2-
transformed cells. 
Figures 3.1.28-3.1.29 
The expression of tubulin-a in the NRP-152 cells by immunofluorescence. 
Fig. 3.1.28 
The presence and localization of tubulin-a are shown in the parental NRP-152 cells. 
The bright spots (white arrows) at the periphery of the cells may represent the 
localization of centrosomes (x 400). 
Fig. 3.1.29 
The expression of tubulin-a in the Ez-transformed NRP-152 cells by 
immunofluorescence is demonstrated. A weaker fluorescent signal was observed 
when compared with the parental cells (x 400). 
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Figures 3.1.30 - 3.1.31 
The ultrastructural study of the untreated NRP-152 cells by electron microscopy. 
Fig. 3.1.30 
A well-differentiated NRP-152 cells with a centrally located nucleus is illustrated 
(X 4,000). 
Fig. 3.1.31 
A higher magnification of mitochondrion is demonstrated. Organelles, such as 
mitochondria and rough endoplasmic reticulum, can be seen (x 7,000). 
Figures 3.1.32-3.1.35 
The ultrastructure of the E2-transformed NRP-152 cells by electron microscopy. 
Fig. 3.1.32 
The ultrastrucutre of mitochondria in an E2-transformed NRP-152 cell at a higher 
magnification is demonstrated. Reduced infoldings of the inner membrane and 
cristae and increased matrix can be seen (x 20,000). 
Fig. 3.1.33 
Myelinated nuclear membrane is observed in an E2-transformed NRP-152 cell 
(X 20,000). 
Fig. 3.1.34 
The presence of an increased number of secondary lysosomes in the E2-transformed 
cells is demonstrated (x 10,000). 
Fig. 3.1.35 
Disorganized, rather than well-organized, microtubules are observed in the E2-
transformed cells (x 50,000) 
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The protein expression in the control NRP-152 cells and the E2-tranformed cells by 
Western blottings. Protein expression of the four E2-transformed clones relative to 
that of P-actin is shown in an arbitrary unit. Protein expression of the parental cells is 
adjusted as 1 for comparison. 
Fig. 3.1.36 
An equal intensity of p-actin 42 kDa) in the parental NRP-152 cells and the 
estrogen transformed cells indicated equal amount the protein was loaded for 
analysis. 
Fig. 3.1.37 (a)-3.1.37 (d) 
Expression of ERa by Western blotting. Three bands are observed in the SDS-
PAGE. An increased of the native ERa 67 kDa) expression is seen in the samples 
obtained from the E2-tranformed cells. 
Fig. 3.1.38 (a)-3.1.38 (b) 
The expression of ERp by western blotting is demonstrated. ERp expression is 















































































































































































































































































































































































































































































































Fig. 3.1.39 (a)-3.1.39 (b) 
A down-regulation in AR expression can be observed in the E2-tranformed cell 
samples, as compared with the untreated parental cell sample. The lost in AR 
expression is obvious in E2-tranformed clone no. 1. 
Fig. 3.1.40 (a)-3.1.40 (b) 
Expression of tubulin-a by Western blotting. Difference in tubulin-a expressions 
between the control cell sample and the E2-tranformed cell samples is not obvious. 
Fig. 3.1.41 (a)-3.1.41 (b) 
Decreased expression of PTEN can be observed by Western blotting. A significant 



























































































































































































































































































































































































































The expression of Rap 1 is demonstrated. A slight increase in Rap 1 expression in the 
E2-tranformed cells is shown. 
Fig. 3.1.43 
Decreased BRCA2 expression is seen in E2-tranformed clones no of cells (except 
clone no. 2) by Western blotting. It may suggest the expression pattern of BRCA2 
may be related to the degree of transformation. 
Fig. 3.1.44 
Various SOD-1 expressions are observed among the E2-transformed cells by Western 
blotting. An increase in SOD-1 expression is observed in the E2-transformed clones 
















































































































































































































































































































































































































































































































Noble rat showing the inflammation of prostate (white arrow) after perinatal 
exposure to estrogen and long-term hormone treatment. 
Figure 3.2.2 
Prostate tumor (white arrow) induced by perinatal estrogen imprinting and long-term 
hormone treatment is shown. 
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The Noble rat prostate after 
perinatal estrogen imprinting and hormone treatment 
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Figures 3.2.3 - 3.2.5 
The three lobes of the control Noble rat prostates. 
Fig. 3.2.3 
The histology of the ventral prostate (VP) of a control Nb rat is demonstrated. Nuclei 
of the epithelial cells are located at the basal sides of the cells. Large lumens are 
present in VP (x 100). 
Fig. 3.2.4 
The histology of the lateral prostate (LP) of a control Nb rat. Smaller lumens with 
epithelial infoldings are observed in the LP (x 100). 
Fig. 3.2.5 
The histology of dorsal prostate (DP) of a control Nb rat. Larger acini are lined by 
pseudostratified or simple columnar epithelial cells. Eosinophilic secretion also 
characterizes the DP (x 100). 
Figures 3.2.6 - 3.2.8 
Fig. 3.2.6 
The histology of VP of an estrogen-imprinted and hormone treated Nb rat. Prostatic 
intra-epithelial neoplasia (PIN) of flat and tufting patterns are observed (x 100). 
Fig. 3.2.7 
High-graded PIN of micropapillary pattern is shown in the LP of an estrogen-
imprinted and hormone-treated Noble rat (x 100). 
Fig. 3.2.8 
Lesions in the DP of a Nb rat after perinatal estrogen-imprinting and hormone 
treatment is shown. Proliferation of epithelial cells along the lumen of the acini is 
observed. Intra-acinar cell proliferation is also demonstrated (x 100). 
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Morphology of the rat prostate by H & E staining 








Immunohistochemical study on ERa expression in the control Nb rats. The epithelial 
cells are not stained with ERa while the nuclei of the stromal cells underneath the 
acini are moderately stained with ERa (x 200). 
Figures 3.2.11 -3.2.14 
Fig. 3.2.11 
An increase expression of ERa is observed in the mesenchymal cells underneath the 
acini after perinatal estrogenization and long-term hormone treatment (x 100). 
Fig. 3.2.12 
ERa expression is observed in the nuclei of the proliferated stromal cells (x 200). 
Fig. 3.2.13 
A strong ERa immunoreactivity is demonstrated in the mesenchymal cells after 
estrogen exposure. Disrupted stromal cell layer is also shown (x 200). 
Fig. 3.2.14 
ERa is expressed in the stromal cell but not the epithelial cells (x 200). 
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Results 
Figures 3.2.15 - 3.2.16 
The immunostaining of ERp in the control Nb rat prostates. Strong and clear nuclear 
staining are observed in the epithelial cells (Fig. 3.2.15, x 200; Fig. 3.2.16, x 100). 
Figures 3.2.17-3.2.20 
The expression of ERp in the Nb rat after perinatal estrogen-imprinting and hormone 
treatment. 
Fig. 3.2.17 
ERP is expressed in the nuclei of the epithelial cells lining the acini where only 
glandular enlargement and increased infoldings were observed (x 200). 
Fig. 3.2.18 
A significant loss of nuclear ERp expression was observed when adenocarcinoma is 
induced by the estrogen treatment (x 100). 
Fig. 3.2.19 
An overall decrease in ERp expression is shown when intra-epithelial cells 
proliferate and growing into the lumen of the acini. Positive ERp staining is observed 
in the epithelial cells which is at the basal part of the proliferated epithelium (x 200). 
Fig. 3.2.20 
This figure shows a decrease in ERp expression some pre-malignant areas (x 100). 
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Results 
Figures 3.2.21 - 3.2.22 
The immunostaining of AR in the control Nb rat prostates. 
Fig. 3.2.21 
A strong nuclear staining of AR is shown in the epithelial cells, indicating the 
presence of AR in prostatic epithelium (x 200). 
Fig. 3.2.22 
A higher magnification showing the nuclear localization of AR in the prostatic 
epithelium (x 400). 
Figures 3.2.23 - 3.2.26 
The immunoreactivity of AR in Nb rat prostate with perinatal estrogenization and 
hormone treatment. 
Fig. 3.2.23 
A significant loss of AR in the prostatic epithelial cells when prostatic lesions 
develop (x 100). 
Fig. 3.2.24 
Low to moderate nuclear AR expression can also be seen in the epithelial cells when 
low-graded PIN and hypertrophy develop after estrogen treatment (x 200). 
Fig. 3.2.25 
Another figure showing the reduction of nuclear AR expression in the epithelial cells 
(X 200). 
Fig. 3.2.26 
Some epithelial cells can still be immunolabeled by AR antibodies while some of the 
epithelial cells show a loss in AR expression after estrogen-imprinting and hormone 
treatment (x 200). 
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Results 
Figures 3.2.27 - 3.2.28 
The expression of tubulin-a in the prostatic cells of the control Nb rats is shown. 
Both figures illustrate that tubulin-a is highly expressed in the cytoplasm of the 
prostatic epithelial cells, particularly the apical cytoplasm (Fig. 3.2.27, x 200; Fig. 
3.2.28’ X 200). 
Figures 3.2.29 - 3.2.32 
Fig. 3.2.29 
Cytoplasmic expression of tubulin-a is significantly lost in the estrogen-imprinted 
and hormone treated Nb rat prostate where intra-epithelial cells proliferate and grow 
into the lumen of the acini (x 100). 
Fig. 3.2.30-3.2.31 
An overall decrease in tubulin-a expression is demonstrated, although 
immunostaining of tubulin-a can still be observed in some of the prostatic epithelial 
cells (Fig. 3.2.30’ x 200; Fig. 3.2.31, x 200). 
Fig. 3.2.32 
Adenocarcinoma lesion is developed. It shows that tubulin-a expression is severely 
down-regulated in the cytoplasm of the prostatic cells (x 200). 
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Tubulin-g expression by immunohistochemistry 
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Results 
Figures 3.2.33 - 3.2.34 
PTEN expression in the control Noble rat prostates. Moderate immunostaining 
intensity can be seen in the cytoplasm of the luminal epithelial cells in a control Nb 
rat prostate (Fig. 3.2.33’ x 200; Fig. 3.2.34, x 400). 
Figures 3.2.35 - 3.2.38 
PTEN expression is severely lost when prostatic lesions are induced by perinatal 
estrogen-imprinting and hormone treatment at adulthood. This loss can be observed 
when low-graded PIN (Fig. 3.2.35, x 200), intra-epithelial cells proliferation (Fig. 
3.2.36, X 200; Fig. 3.2.37, x 200), and hypertrophy (Fig. 3.2.38, x 200) are induced 
by estrogen. 
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A moderate cytoplasmic immunostaining of Rap 1 is observed in the control Nb rat 
prostates. 
Figures 3.2.40-3.2.41 
Expression of Rap 1 in the estrogen-imprinted and hormone treated Nb rat prostates. 
Fig. 3.2.40 
Various staining pattern of Rap 1 can be seen in this figure. It is observed that Rap 1 
is positively labeled in the prostatic epithelial cells where premalignant lesions 
develop while a loss in Rap is seen in the prostates with intra-acinar epithelial cell 
proliferation and PIN of tufing pattern development. 
Fig. 3.2.41 
The loss of Rap 1 expression is demonstrated in the prostatic epithelial cells in the 
acini where high-graded PIN with tufting pattern develops. 
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Figures 3.2.42 - 3.2.43 
BRCA2 is highly expressed as a strong nuclear staining in prostatic epithelial cells of 
the control rat (Fig. 3.2.42, x 200; Fig. 3.2.43, x 200). 
Fig. 3.2.44 - 3.2.47 
BRCA2 expression in the Nb rat prostate after peinatal estrogenization and long-term 
hormone treatment. 
Fig. 3.2.44 
Positive BRCA2 staining can be observed in the nuclei of the non-cancerous 
epithelial cells lining the acini (on the left of the figure) while positive BRCA2 
staining pattern is greatly reduced when hypertrophy develops in the adjacent acini 
(x 100). 
Fig. 3.2.45 
This figure shows another various BRCA2 immunostaining patterns in the nuclei of 
the prostatic epithelial cells in the estrogen-imprinted and hormone-treated prostates. 
The positively stained epithelial cells are found at the base on the proliferated 
epithelial layers (x 200). 
Fig. 3.2.46 
An obvious loss of BRCA2 expression in the nuclei of the epithelial cells in the 
estrogen-exposed Nb rat prostate is shown (x 200). 
Fig. 3.2.47 
BRCA2 expression is lost in the epithelial cells in the acini where prostatic lesions 
develop whereas at early onset of prostate lesions, as indicated by the proliferation of 
epithelial cells, a relatively higher BRCA2 expression is expressed (x 100). 
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Expression of SOD-1 in the epithelial cells in the control Nb rat prostate is 
illustrated. Positively stained epithelial cells are shown in the cytoplasm, especially 
at the apical cytoplasm of the epithelial cells, thus indicating the presence of SOD-1 
in scavenging free radicals in the cells for oxidative defense (x 200). 
Figures 3.2.49 - 3.2.50 
The immunoreactivity of SOD-1 is shown in the estrogen-imprinted and hormone-
treated Nb rat prostates. 
Fig. 3.2.49 
An obvious loss of cytoplasmic staining of SOD-1 can be seen in most of the 
epithelial cells after estrogen exposure while some of the epithelial cells remained 
unaffected by estrogen and show a positive staining (x 100). 
Fig. 3.2.50 
A severe and prominent loss of SOD-1 expression is demonstrated. When malignant 
prostatic lesions develop, immunoreactivity of SOD-1 is lost. This lost suggests that 
the production of superoxide dismutase is down-regulated by estrogen exposure, thus 
leading to prostatic lesions development (x 100). 
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Chapter 4. Discussion 
4.1 The study on the transformation of cells and soft agar assay 
Transformation is an introduction of inheritable changes in a cell. It causes 
changes in the growth phenotype and immortalization. Transformation of cells in 
culture is the in vitro counterpart of tumor initiation and promotion in animals. 
Transformed cells show several characteristics that can distinguish them from 
the normal and the immortal cells (Crane, 1999). These characteristics are as follows: 
(1) Altered morphology. The morphology of the transformed cells would be different 
from the cells they are transformed from. The shape of the cells is changed as cells 
grow without inhibition in monolayer. Besides, transformed cells lose parallel 
orientation. (2) Lost of contact inhibition. Normal cells exhibit cell-cell inhibition 
during growth. When confluency is reached, cells would cease to divide due to cell-
cell inhibition. On the contrary, transformed cells do not possess this characteristic 
and so they would continue to grow and become crowded when confluency is 
reached. (3) Increased growth rate. The doubling time of transformed cells generally 
is shorter than that of the normal cells. (4) Anchorage-independent growth. 
Transformed cells exhibit anchorage-independent growth. The transformed cells 
usually can grow in semi-solid substratum, such as soft agar, and form colonies with 
a higher efficiency than the untransformed cells. Usually, it is predicted that 
anchorage independent growth is highly related to the tumor-forming ability of the 
transformed cells in animals (LeBoeuf et at, 1996). (5) Tumorigenicity. When 
transformed cells are injected to the immunoincompetent mice, e.g. nude mice, 
tumors can be produced. These phenomena are often used as parameters to primarily 
detect the transformation of cells. 
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Several studies were carried out to study the untreated parental and E2-
transformed NRP-152 cells. These studies include the followings: (1) Morphological 
study. It was found that E2-transformed cells were more irregular in shape while the 
untreated parental cells appeared oval in morphology. Besides, when the cells grew 
to confluency, the boundary between individual cells was unclear in the E2-
transformed clones of cells. Cells tended to grow in colony when the seeding number 
of cells was small. (2) Anchorage-independent growth. Soft agar assay showed that 
parental NRP-152 cells did not grow well in soft agar while E2-transformed cells 
could grow as cell aggregates with an efficiency higher than the parental cells. 
Colonies larger than 100 nm in diameter could also be developed from the single 
cells seeded in soft agar. (3) Studies of growth parameters: doubling time (DT) and 
colony forming efficiency. The DT of the Ez-transformed cells was increased when 
compared with the parental cells, indicating that a longer time was needed for 
doubling its cell number at log phase. Ej-transformed NRP-152 cells showed higher 
colony-forming efficiencies than the parental cells, suggesting the induction of 
anchorage-independence in the E2-transformed cells by estrogen treatment. (4) 
Tumorigenicity in nude mice. When E2-transformed cells and untreated parental cells 
suspended in Matrigel were injected into nude mice subcutaneously for about one to 
three months, no tumor was developed. This suggested that transformation induced 
by estrogen was not effective enough to allow the growth of these E2-transformed 
NRP-152 cells into tumors in the nude mice. 
Based on these observations, it showed that single estrogen treatment might 
act on and transform the immortalized prostatic epithelial cell line NRP-152. The 
NRP-152 could be transformed by E2 as it exhibited several characteristics, like 
morphological changes, lost of contact inhibition and anchorage independent growth 
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in soft agar. However, the growth rate was decreased rather than increased as the 
doubling time appeared to be longer after estrogen treatment. The Ez-transformed 
NRP-152 cells showed no tumorigenicity in nude mice. 
There are several possible explanations for the failure to develop tumors in 
nude mice although colonies can be formed in agar by the Es-transformed NRP-152 
cells. Firstly, tumorigenicity depends on the number of transformed cells showing 
anchorage-independent phenotypes. There may be only a small fraction of cell 
population that expresses anchorage-independent phenotype after estrogen treatment. 
As the seeding of cells for anchorage independent assay is random, the probability to 
isolate the transformed cells with anchorage-independence would be affected. 
Besides, i f the potential transformed cells are not seeded for agar assay or are not 
passaged, transformed cells with anchorage-independent phenotype may be lost. 
Moreover, some of the Ez-transformed cells may be not yet about to express 
anchorage-independence. In addition, transformation is a multistep process and more 
than one gene mutation is involved. Thus, prolonged use of estrogen would be more 
successful in inducing the changes required to effect transformation (Barrett & Ts’o， 
1978; Crane, 1999) and the consequent tumorigenicity. 
4.2 Growth pattern of the estrogen-transformed clones 
One of the characteristics of transformed cells is an increase in growth rate 
(Crane, 1999), meaning that cells can double their number within a shorter period of 
time when compared to the normal cells. When E2-treated NRP- 152 cells grown in 
the soft agar were selected and successfully expanded, they were considered as E2-
transformed cells. However, it was found that the doubling time of the E2-
transformed NRP-152 cells were longer (21.59 土 1.39 hr, 23.39 土 2.34 hr, 22.15 ± 
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0.49 hr and 23.77 土 2.87 hr for the Ez-transformed clones 1,2,3 and 4 respectively) 
when compared with the untreated parental cells ( 1 6 . 6 2 土 0 . 4 6 hr), suggesting that 
the E2-transformed cells were growing slower than the untreated parental NRP-152 
cells. This may be due to the use of estrogen as the transforming agent in the NRP_ 
152 cells. Estrogen may act as a microtubule-disrupting agent. Tsutsui et al (2000) 
report that 2-Methoxyestradiol (2-MeOE2)’ an endogenous metabolite of estrogen, 
can bind to the colchicine site of tubulin and inhibit microtubule assembly (D'Amato 
et al, 1994). Fragmented centrosomes, multiple polar formations and abnormal 
spindle formations are shown in MCF-7 and HeLa cells treated with 2-MeOE2 
(Tsutsui et al, 2000). The decreased doubling time in the Es-transformed clones of 
NRP-152 cells may be due to the abnormal dynamics of microtubule formation in the 
cytoskeleton and thus the mitotic spindle figure. As a result, the rate of cell division 
may be affected and slowed down by the disrupted microtubules and cytoskeletons. 
4.3 Altered differential gene expression 
Alternation of different gene expression was studied by cDNA microarray. 
Two gene arrays were used to study the expression of genes in the Ez-transformed 
cells. Four interested genes with differences and fold changes in gene expression 
were selected. These genes included TUBAS, PTEN, RAPIA (androgen signaling and 
prostate cancer gene array) and BRCA2 (DNA damage signaling pathways array). 
4.3.1 TUBAS 
TUBA3 (a gene switched from androgen responsive to androgen independent 
in recurrent prostate cancer after hormone therapy) encodes the tubulin-a protein. 
Tubulin-a composes the tubulin which forms into microtubules and takes part in 
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cellular functions such as chromosome segregation and structural support in the 
cytoskeleton. 
A study on the Aspergillus nidulans shows that molecular disruption of TUBA 
can lead to a block in nuclear division (Doshi et al, 1991). Moreover, the effects of 
estrogens on the cytoplasmic microtubule network are examined in a human breast 
cancer cell line. Aizu-Yokota et al (1994) find that estradiol decreases the amount of 
cytoplasmic microtubule fibers during interphase and diethylstilbestrol (DES) also 
induces microtubule reduction. 
It was found that the gene expression of TUBA3 in the Ez-transformed cells 
was significantly down-regulated (fold change = -10.09). When comparing this result 
with previous findings, the amount of microtubules is reduced by estradiol. It may 
suggest that estrogen used to induce transformation in NRP-152 cells may decrease 
the amount of tubulin-a available for the formation the microtubules. 
4.3.2 PTEN 
P T ™ (an androgen-independent prostate cancer related gene) is a 
suppressor gene which maps to chromosome 10q23. Defective PTEN tumor 
suppressor gene is found to be involved in a large number of human cancers, such as 
endometrical, renal cancers as well as prostate cancers (Cantley & Neel, 1999). 
Inactivation of PTEN during tumor progression may lead to tumor cell dissemination 
(Kotelevets et al, 2001). 
In the present study, a decreased radioactive signal representing PTEN was 
detected in the sample from Ez-transformed NRP-152 cells (fold change = -2.538) 
when compared with the untreated parental cells. The decrease indicated a significant 
down-regulation of PTEN in the E2-transformed NRP-152 cells. This result is 
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comparable to the finding by Kotelevets et al (2001) that PTEN is inactivated during 
tumor progression. This loss of PTEN in Es-transformed NRP-152 cells may 
therefore suggest estrogen may induce transformation in prostatic cells through the 
inactivation of PTEN. 
4.3.3 RAPIA 
Rap]A (a gene associated with invasive prostate cancer) is a /?fl5-related 
tumor suppressor gene (Wani et al, 1997). Together RaplB, these two genes encode 
95% homologous 21 kDa protein that shares with Ras protein (Pizon et al, 1988). 
Expression of Rap 1 gene has been reported to revert the transformed cells to a flat 
morphology so that the reverted cells can reestablish contact inhibition and cannot 
form colonies in agar (Wani et al, 1997). 
In transformed mouse embryo fibroblasts, introduction of Rap 1 can reverse 
the transformed phenotype and suppress Ras induced genomic stability (Wani et al, 
1997). From the gene expression observed in the microarray, a reduced Rap 1 gene 
expression was observed in the E2-transformed cells (fold change = -1.633). This 
decrease may suggest that estrogen may suppress the expression of Rap IA and thus 
favor the transformation of prostatic cells. 
4.3.4 BRCA2 
5/?C42 (a gene involved in genomic stability) is a tumor suppressor gene. 
Mutational disruption of BRCA2 is recognized as a causative factor of hereditary 
breast cancer and ovarian cancers (Wooster et al, 1994; Ford et al, 1998). Tutt et al 
(1999) report that chromosome missegregation and aneuploidy are related to the loss 
of BRCA2. Besides, centrosome number is amplified and spontaneous micronuclei 
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containing lagged chromosomes, a marker of chromosome instability, are developed 
in the absence of BRCA2 (Tutt et al, 1999). 
A decreased expression in BRCA2 was observed in the E2-transformed NRP-
152 cells (fold change = 5.18). Reduced BRCA2 expression would lead to 
chromosome instability as spontaneous micronucleus is developed and the 
centrosome number is increased (Tutt et al, 1999). Centrosomes nucleate mitotic 
spindles and form poles of division at mitosis and thus an abnormal number of 
centrosomes may disrupt chromosome segregation (Tutt et al, 1999). It is therefore 
hypothesized that estrogen may transform the NRP-152 cells through reducing 
BRCA2 expression through which loss of chromosome instability is induced. 
4.4 Ultrastructural study in estrogen-transformed and untreated 
parental NRP-152 cells 
The electron microscopy study demonstrated several ultrastructural 
alternations between the E2-transformed and untreated parental NRP-152 cells. 
Mitochondrial components are targets of free radical damage especially 
associated with aging (Borras et al, 2003). One of the obvious alternations found in 
the E2-transformed NRP-152 cells was the disruption of inner membrane of the 
mitochondria. Focal loss of infoldings and increased amount of matrix were observed 
in the mitochondria of the Ei-transformed cell. A decrease in densely-packed cristae 
was also seen. This finding demonstrated that E) exerted a damaging effect in the 
mitochondria. Apart from nuclear genome, mitochondria also possess their own 
DNA. Estradiol used to treat the NRP-152 cells may be metabolized into catechol 
estrogen (CE) which in turn can form DNA adducts (Cavalieri et al, 1997). When E〗 
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was applied to induce the transformation of cells, catechol estrogen quinones (CE-Q) 
and catechol estrogen semiquinones (CE-SQ) might react with the mitochondrial 
DNA, forming DNA adducts or depurinating adducts. Mitochondrial genes have 
been identified for the coding of ribosomal RNA (rRNA), transfer RNA (tRNA) and 
some subunits of enzymes involved in the oxidative phosphorylation. Thus, the 
damage in mitochondrial DNA by estrogen may affect the phenotype and the normal 
functionings of the mitochondria in the expression of rRNA, tRNA and respiratory 
proteins. 
The observation of distorted inner membrane may also suggest that the 
respiratory chain reaction by oxidative phosphorylation is affected (Cavalieri et al, 
1997). The major function of mitochondrion is energy production in cells. Inner 
membrane accommodates enzyme complexes responsible for oxidative 
phosphorylation. The distorted inner membrane structure with decreased number of 
cristae may suggest that the respiratory chain activity of the distorted mitochondria 
would be altered or damaged. This in turn would influence the capability of the 
mitochondria for ATP generation. It is speculated that the damages in microtubule 
assembly and mitochondria would affect cell division, thus giving rise to a longer 
doubling time in the E2-transformed cells. 
Another structural change found in the E2-transformed cells was the 
myelination of nuclear membrane. One of the components of nuclear membrane is 
lipid. Lipid is one of the targets that ROS may attack as lipids are readily peroxidized 
(Cavalieri et al, 1997). During prooxidant conditions, lipid hydroperoxides are 
formed. Estrogen can induce lipid peroxidations during estrogen metabolic 
activation. The products of the peroxidized lipid often take part in a chain reaction 
propagating formation of radical species (Cavalieri et al, 1997). As nuclear 
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membrane contains lipids, it may be the target of ROS formed from estrogen 
metabolism. That may explain the abnormal formation of nuclear membrane. 
An increase in secondary lysosomes were observed in the E2-transformed 
cells. As secondary lysosomes are the site of intracellular digestion (Becker et al, 
1996), particularly for the damaged organelles such as mitochondria, it may suggest 
estrogen may damage the cells and their organelles during transformation. 
The observation of the disorganized microtubules in the E2-transformed NRP-
152 cells may suggest that estrogen may act as a microtubule disrupting agent which 
may inhibit microtuble assembly. 
4.5 Neoplastic lesions induced in prostates of estrogen-imprinted 
and long-term combined hormone treated Noble rats 
In this study, various grades of premalignant and neoplastic lesions were 
induced in the prostates of estrogen-imprinted and further combined androgen and 
estrogen treatment in male Noble (Nb) rats. Epithelial proliferative lesions, including 
hyperplasia, low-graded and high-graded PENs and carcinoma in situ, were observed 
in the estrogen-treated ventral prostate (VP), lateral prostate (LP) and dorsal prostate 
(DP). Our present observation on the pathological proliferation lesions induced in the 
VP and LP of Nb rats agrees with previously findings as reported in the rats and mice 
with perinatal estrogenization or prolonged combined hormonal treatment in the 
adult Nb rats (McLachlan et al, 1975; Leav et al, 1988, Leav et al, 1989; Kwong et 
al, 2003). Besides, our present observation on the induction of PEN and neoplasia in 
the DP is novel and has not been reported previously. The DP appears to be resistant 
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to develop pathological changes in the established protocols of combined hormonal 
treatment for duration up to 6 months. 
McLachlan et al (1975) report that adenocarcinoma and hyperplasia are 
induced in the coagulating gland and hyperplasia in the VP of the neonatal DES 
exposed male CD-I mice, whose mother was pre-treated with DES during the 
gestation days 9-16. Subsequently, Pylkkanen et al (1991; 1992) also observed that 
epithelial dysplasia is induced in the periurethral proximal parts of dorsolateral 
prostates (DLP) and coagulating glands of HaniNMRI mice. In addition, squamous 
cell carcinoma is developed in the dorsolateral prostates, and hyperplasia and 
squamous metaplasia are induced in the coagulating gland of Wistar rats which are 
exposed to DES neonatally. In this study, the results that various prostate lesions are 
observed in the Noble rats being treated with DES perinatally with further combined 
hormone treatment are in concord with those findings in which mice being 
administrated by exogenous estrogen during the critical time of prostate development 
(prenatal or neonatal) can result in permanent imprinting effects. It appears that this 
estrogen imprinting effect induced by early estrogen exposure enhances the 
combined hormone treatment in the induction of prostatic neoplastic lesions in the 
adult male rats. 
Combined treatments with both androgen and estrogen or long-term treatment 
with estrogen alone but not single treatment with androgen can induce various grades 
of premalignant and neoplastic lesions in DLP and VP in Noble rats. The degree of 
grading of these lesions depends on the dosage of testosterone (not DHT) and 
duration of treatment (4-12 months) (Drago, 1984; Leav et al, 1989). These 
treatments demonstrate the importance of and the possible involvement of estrogen 
in the process of hormone-induced carcinogenesis of prostate. Our present findings 
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in the early exposure to estrogen on the development and induction of neoplastic 
lesions in all three lobes of rat prostate support the importance of estrogen 
carcinogenicity. In the original Nobel rat model of prostate cancer, Noble (1982) 
uses only pellets of testosterone propionate (subcutaneous implantation). 
Subsequently, Drago et al (1984) developed the combined treatment with both 
testosterone and E1/E2 (subcutaneous implantation of pellets of testosterone and 
Ei/E2-filled Silastic tubings). By this combined treatment, the induction period of 
lesions in the DLP is shortened. Microscopic carcinoma are found in the DLPs of the 
majority of intact Nb rats being treated with T+ E2 Silastic implants for a long period 
of time. Leav et al (1988) also confirms the combined use of T+E2 in triggering the 
development of prostatic dysplasia within the DLP. It suggests that prostatic 
dysplasia is mostly developed in the LP and VP after this combined treatment 
(Kwong et al, 2003). Besides, the use of the modified protocol of combined hormone 
treatment demonstrates that the induction of premalignant and neoplastic lesions 
would be at a higher incidence rate and within a shorter period of time when the 
amount of T and E2 used are increased, as compared to the protocols of Leav et al 
(Wang & Wong, 1998). The present study also showed that combined hormone 
treatment could enhance premalignant and neoplastic lesions of various grades 
including hyperplasia, PIN and adenocarcinoma, in the estrogen-imprinted rat 
prostates. The combined effect of perinatal estrogen and long-term hormone 
treatment may act as a strong inducer in the development of prostatic neoplastic 
lesions in the rat prostate, as supported by the induction of lesions in DP which is 
resistant to combined hormonal treatment. PIN and neoplastic lesions are rarely 
induced by combined hormone treatment in DP. DP is considered to be resistant to 
abnormal cell growth as compared to VP and LP. The development of prostate 
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lesions in DP in this study suggests that the early estrogen exposure during prostate 
development would result in a permanent imprint in the prostates (Prins et al, 2001b) 
and prolonged hormone treatment at adulthood would enhance the occurrence and 
increase the severity of prostatic lesions (e.g. hyperplasia, inflammation and 
dysplasia). 
4.6 Altered protein expressions in estrogen-transformed NRP-152 
cells and estrogen-imprinted and hormone-treated Noble rat 
prostates 
The protein expression of some markers were examined and compared 
between the E2-transformed and the untreated parental NRP-152 cells {in vitro 
study) and between the estrogen-imprinted and hormone treated and the control Nb 
rat prostates (in vivo study). 
4.6.1 Alteration in steroid hormone receptors 
Steroid receptors under investigated were the estrogen receptor a (ERa), 
estrogen receptor p (ERp) and androgen receptor (AR). 
(a) Estrogen receptor a (ERa) 
ERa is the classic ER. Its expression is confined to mesenchymal cells in the 
proximal region of the prostate gland (Cooke et al, 1991; Prins & Birch, 1997). 
(i) In vitro study 
A similar ERa expression was observed in the E2-transformed NRP-152 cells 
when compared with the parental NRP-152 cells. In Western blot analysis, three 
isoforms of ERa can be detected (Geffroy-Roisne et al, 1993). One of the isoforms is 
the native ERa that is about 67 kDa and it is identified in rodent uterus (Jensen & 
1 3 2 
Discussion 
Jacobsen, 1962). The other two isoforms are the putative ERa of ~ 50 kDa and ~ 54 
kDa. ERa isoforms have been suggested to be related to the proteolytic cleavage and 
phosphorylation of receptor protein or the possible association of the receptor with 
other carrier protein. 
The native ERa 67 kDa) and the two putative ERa 54 kDa and ~ 50 
kDa) were observed by Western blowings. An increase in colorimetric intensities of 
the native ERa was observed in the E2-transformed cells when compared with the 
parental NRP-152 cells. Meanwhile, slight decreases in the expressions of the two 
putative ERa were detected. ERa is demonstrated in the ERa and ERp null mice 
that ERa is involved in the induction of prostatic metaplasia (Cunha et al, 2001). 
Based on this study, the increased expression of native ERa after estrogen exposure 
may postulate that estrogen may induce abnormal prostatic growth and cell 
transformation via native ERa 
(ii) In vivo study 
Previous studies on the ERa expression in the normal prostate gland find that 
ERa expression is low and is restricted to the mesenchymal cells surrounding the 
prostate ducts (Prins et al, 1998). An up-regulation of ERa expression was observed 
in the stromal cells along the length of the prostatic ducts in the neonatally 
estrogenized rats (Prins et al, 2001b). 
Similar observation was found in the present study. From the result of 
immunohistochemistry, it was found that the expression of ERa was increased 
obviously in the stromal cell of the perinatal estrogen-imprinted Nb rats. This 
increase in ERa expression suggests that ERa is dominant in mediating estrogen 
action during perinatal estrogen exposure (Prins et al, 2001a; Prins et al, 2001b) as 
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estrogen has to act on its receptors to exert its effect to its target tissue. The up-
regulated expression of ERa also indicates that estrogen signal induced perinatally to 
the male Nb rats is amplified by this increased number of ERa present in the stromal 
cells (Prins & Birch, 1995). As exposure to estrogen during the critical period of 
prenatal and neonatal prostate development in rats can significantly alter the ERa 
expression pattern within the prostate (Prins et al, 2001b), the developing prostate of 
the perinatal ly estrogen-treated Nb rats is switched to an estrogen-regulated, rather 
than an androgen-dominated, tissue. A stromal-mediated estrogenization of the 
prostate is induced as described by Prins et al (2001b). We hypothesize that this 
estrogenization of the prostate gland may accelerate the process of hormone-induced 
carcinogenesis through the up-regulation of stromal ERa. 
(b) Estrogen receptor p (ERp) 
ERp is another isoform of ER besides ERa. It is highly homologous to ERa 
in the DNA binding domain but is differed from ERa in the DNA binding domain 
and the transactivation domains. ERp is highly expressed in the nuclei of the 
prostatic epithelial cells (Lau et al, 1998; Chang & Prins, 1999; Zhang et al, 2001). 
(i) In vitro study 
In the untreated parental NRP-152 cells, a positive expression of ERp in the 
nuclei was detected. This staining pattern agrees with the finding in the normal rat 
and human prostatic epithelial cells that ERp is observed in the prostatic epithelial 
cells. By immunohistochemistry, a decrease in ERp expression was observed in the 
E2-transformed cells. The results of Western blottings also demonstrated that ERp 
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60 kDa) expression was decreased in the E2-transformed NRP-152 clones of cells, as 
compared to the untreated parental NRP-152 cells. 
It has been reported that pERKO mice would develop into hyperplasia at old 
age (Krege et al, 1998) and it is postulated that ERp may be involved in the 
antiproliferative growth of the mature prostate (Chang & Prins, 1999). The present 
findings of the decreased expression of ERp by both immunohistochemistry and 
Western blottings suggest exposure of estrogen may decrease ERp expression. This 
decreased ERP expression in the prostatic epithelial cells may thus lead to the loss of 
antiproliferative growth regulation in the prostate. Therefore, it is suggested that 
estrogen may induce transformation in the prostatic epithelial cells by interfering the 
growth inhibitory effect through suppressing the ERp expression, 
(ii) In vivo study 
In the control prostate gland, ERP was mostly localized in the nuclei of the 
prostatic epithelial cells. The observation of the expression of ERp in the epithelium 
of the control prostate was in agreement with previous findings (Lau et al, 1998; 
Chang & Prins, 1999; Zhang et al, 2001). 
Previous findings show that ERP knockout mice can develop prostatic 
hyperplasia with aging (Krege et al, 1998) and that the proliferation of the prostatic 
cancer cells which express ERp would be inhibited by anti-estrogens (Lau et al, 
2000). Apart from these, a down-regulation of ERp is detected during prostatic 
carcinogenesis and tumor progression (Leav et al, 2001). Early exposure of estrogen 
would down-regulate the expression of ERp in the epithelium of DLP (Prins et al, 
1998; Makela et al, 2000), suggesting the involvement of ERp in the 
antiproliferation of prostatic cells (Chang & Prins, 1999). In the present study, a 
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decreased expression of ERp was observed in the PIN area in the perinatal estrogen 
imprinted and hormone treated Nb rat prostates. Therefore, it may suggest that 
estrogen may contribute to the abnormal proliferation of prostatic epithelial cells by 
down-regulating the expression of ERp, thus leading to the lost of the inhibitory 
action by ERp in regulating prostatic cell growth. 
The altered expression of ERa and ERp in the prostatic cells in both the in 
vitro and in vivo studies after the exposure of estrogen may suggest that estrogen 
may exert its effect in the prostate gland through the mediation of ER. 
(c) Androgen receptor (AR) 
AR plays an important role in prostate gland as AR can direct the growth and 
differentiation of the androgen-dependent prostates through the induction of 
paracrine and autocrine factors in the developing prostates (Prins et al, 2001b). 
(i) In vitro study 
By immunohistochemistry, a positive strong immnuoreactivity was observed 
in the nuclei of the parental prostatic epithelial NRP-152 cells while a reduced 
immunoreactivity was detected in the E2-transformed clones of cells. The result of 
Western blottings also agreed with the immunohistochemical study of AR in the 
NRP-152 cells. AR (〜110 kDa) expression was decreased in the E2-transformed 
cells, as compared with the untreated parental NRP-152 cells. These observations 
suggest that the expression of AR may be down-regulated in the exposure of 
estrogen. 
(ii) In vivo study 
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In the control Nb rat prostate, the immunoreactivity of AR was localized to 
the nuclei of the prostatic epithelial cells, suggesting that the receptor was 
functioning in the epithelial cells. Expression was significantly down-regulated in the 
epithelial cells in the Nb rat prostate gland (VP, LP and DP) after estrogen-
imprinting and hormone treatment. The decrease was obvious in the proliferating 
epithelial cells developing PEN. 
Studies have been performed in mice (Prins et al, 2001a; Prins et al, 2001b) 
and rats (Ami et al, 1983) for neonatal estrogenization. Prins and Birch (1995) show 
that the protein expression of AR in rat prostates would be rapidly down-regulated 
after neonatal estrogen exposure. Prins (1992) and Prins et al (1993) also 
demonstrate that androgen action in the rat prostate is interrupted by estrogen 
exposure. These findings may suggest that the decrease in AR expression in the 
estrogen-imprinted and hormone-treated Nb rat prostates observed in the present 
study may be due to the perinatal estrogen imprinting effect. 
The reduced expression of AR in the estrogen-imprinted and hormone-treated 
Nb rat prostates by immunohistochemistry matches the results obtained in the E2-
transformed NRP-152 cells by immunohistochemistry and Western blottings. This 
decreased in AR expression is comparable with the finding that AR expression is 
down-regulated in the rat prostates soon after estrogen exposure (Prins & Birch, 
1995). Both the in vivo and the in vitro studies suggest that estrogen may exert its 
effects on prostatic cells by down-regulating the expression of AR. 
The normal regulatory pathway on the prostate growth mediated through sex 
hormones and their responses may be altered by the altered expression of ERa, ERP 
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and AR. It has been demonstrated by tissue combination studies that under the 
normal influence of androgen, stromal cells stimulate the growth and differentiation 
of prostatic epithelial cells via AR (Cunha et al, 1996). As epithelial cells 
differentiate, AR would be further increased in the expression level (Prins et al, 
2001b). On the contrary, the decrease in AR in prostatic epithelial cells as a result of 
estrogen imprinting would remove or reduce the androgen signaling pathway in the 
developing pathway (Prins et al, 2001b). This alteration in regulatory pathway 
suggests that the developing prostates of the estrogen-imprinted Nb rats would be 
predominantly regulated by estrogen rather than androgen, thus leading to 
morphological imprints and an increase in sensitivity towards estrogen. This increase 
in estrogen sensitivity in the prostate gland would be further amplified and would 
cause damages by the combined hormonal treatment at adulthood. These changes 
may explain the increased susceptibility and severity in prostatic epithelial cells 
proliferation and neoplastic development in the perinatal estrogen-imprinted Nb rats 
further treated with an enhanced hormone treatment (T+E2 or T+DES) in adulthood. 
Besides, the presence of ERs (ERa and ERp) and AR may suggest that there are 
interactions among these receptors on regulating the growth of the prostate. 
4.6.2 Alternation in cytoskeleton (tubulin-a) 
Tubulin-a is one of the two subunits that form the tubulin. Tubulin is a 
dimeric protein of two 55 kDa subunits (tubulin-a & P) (Becker et al, 1996). 
Tubulins would assemble and form microtubule, a major cytoskeletal element, in 
cells. Microtubules are involved in several cellular functions, such as structural 
support and chromosome segregation during mitosis, 
(a) In vitro study 
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From both of the immunohistochemical and immunofluorescent studies in the 
untreated parental NRP-152 cells, abundant well-organized tubulin-a were 
visualized as lateral large aggregates, suggesting tubulin-a are present in the 
cytoplasm of the cells for cellular function in the normal cells. Meanwhile, the NRP-
152 cells showed a marked decrease in cytoplasmic tubulin-a expression in the E2-
transformed cells, as compared to the untreated parental cells. However, a slight 
decrease in the expression of tubulin-a (-57 kDa) was shown in Western blottings. 
The decrease in tubulin-a expression in the E2-transformed prostates agrees 
with previous finding that the amount of cytoplasmic microtubule is decreased by 
estradiol and diethylstilbestrol (DES) during interphase in the human breast cancer 
cells line (Aizu-Yokota et al, 1994). Besides, the application of DES in cultured 
mammalian cells has been reported to be microtubule disrupting that in turn would 
lead to chromosomal aberrations, such as aneuploidy (Tsutsui et al, 1983; Tucker & 
Barrett, 1986). Therefore, it may suggest estrogen may lead to prostatic lesions by 
decreasing the amount and altering the conformation of tubulin-a which may give 
rise to alteration in microtubules, leading to aberrations in chromosome segregation 
during cell division. 
Interesting, in the immunofluorescent study, some bright spots were 
observed at the periphery of the untreated parental cells. These spots may represent 
the presence and localization of the centrosomes. Centrosome is considered to be the 
cellular organizing center for microtubules and it surrounds a pair of centrioles 
whose structure is a cylinder made of microtubules (Becker et al, 1996). Centrosome 
is involved in mitosis as it nucleates spindle pole and determined the axes of mitosis 
(Zimmerman et al, 1999). When comparing the fluorescent signals in the E2-
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transformed cells with those in the parental cells, a marked decrease in the number of 
bright spots was observed, thus suggesting centrosome number may be reduced. 
Centrosome amplification can lead to disordered chromosome segregation and the 
consequent aneuploidy (Tutt et al, 1999) and aneuploidy is related to transformation 
(Lengauer et al, 1998; Li et al, 1997) which usually exhibits an increased growth 
rate. The decreased number of centrosomes observed after estrogen treatment may 
account for the increased doubling time obtained in the E2-transformed NRP-152 
cells. It may suggest that estrogen may decrease the amount of tubulin-a which in 
turn reduces the number of centrosomes and lead to abnormal cell division, 
(b) In vivo study 
A strong cytoplasmic expression of tubulin-a was observed in the epithelial 
cells in the control rat prostates. This illustrated that tubulin-a was present to act as a 
cytoskeleton in the cell under normal condition. The cytoplasmic expression of 
tubulin-a was significantly down-regulated in the epithelial cells of the acini where 
high-graded PIN and carcinoma in situ were developed in the estrogen-imprinted and 
long-term hormone-treated rat prostates. Combining with the results from in vitro 
study, these in vivo results further suggest estrogen may induce transformation by 
reducing the number of the tubulin-a or disrupting the tubulin-a. 
Besides, a diffused staining pattern was observed at the base of the 
proliferated epithelium formed by the dysplastic cells. Kwong et al (2003) have 
reported a similar observation and they find that AR and some secretory proteins are 
expressed in the basal compartment of the PIN. They suggest that there is a 
population of cell types with secretory phenotypes appearing in the basal cell layer 
during early malignant transformation of the prostatic epithelium (Kwong et al, 
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2003). Thus, the expression of tubulin-a observed at the basal epithelium may 
suggest that these cells are a population of cells that proliferate when premalignant 
lesions develop. 
4.6.3 Alternation in PTEN 
PTEN is encoded by the tumor suppressor gene PTEN (Li et al, 1997; Steck 
et al, 1997). It is a putative protein tyrosine phosphatase that is localized to the 
cytoplasm. PTEN shares homology with the cytoskeletal protein tensin and the 
secretory vesicle protein auxilin and also with dual specific phosphatase. PTEN can 
also act as a lipid phosphatase and can inhibit cell cycle progression (McMenamin et 
fl/’ 1999). It can negatively regulate cell growth and/or proliferation (McMenamin et 
fl/, 1999). Kotelevets et al (2001) demonstrate that PTEN is effective in controlling 
invasive phenotype. Overexpression of PTEN is suggested to suppress the formation 
of tumor colony in certain cell line (Furnari et al, 1997; Cheney et al, 1998). From 
the gene transfer studies, it is found that the phosphatase domain of PTEN is 
essential for growth suppression of glioma cells (Furnari et al, 1997). 
(a) In vitro study 
Both the immunohistochemistry and Western blot analysis showed a 
decreased expression of PTEN in the Ez-transformed clones, as compared to the 
untreated parental NRP-152 cells. 
PTEN is overexpressed in certain cell lines to suppress tumor colony 
formation (Furnari et at, 1997; Cheney et al, 1998). Introduction of PTEN into 
fTE/V-lacking cancer cells can negatively regulate cell migration and survival. Loss 
of PTEN expression is detected in xenografts of cell lines (Whang et al, 1998). 
Therefore, the decreased expression of PTEN in the present in vitro study may 
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suggest that estrogen may lead to transformation of cells by down-regulating the 
expression of PTEN. 
(b) In vivo study 
By immunohistochemical study on the Nb rat prostates, a positive and high 
cytoplasmic expression of PTEN was observed in the epithelial cells in the acini in 
the three prostatic lobes of the control rat prostates. This immunostaining pattern 
suggested that PTEN was present to suppress tumor growth in the epithelial cells of 
the acini in the control rat prostates. On the contrary, a decreased in cytoplasmic 
PTEN expression was detected in the prostatic epithelial cells of the estrogen-
imprinted and hormone-treated rats. Moderate immunoreactivity was observed in the 
epithelial cells of acini where hypertrophy or low-graded PIN was developed. In 
high-graded PIN, a significant loss of PTEN expression was found. The down-
regulated expression of PTEN in the dysplastic epithelial cells suggests that the 
ability of negatively regulating cell growth and/or cell proliferation is interfered after 
estrogen imprinting and hormone treatment. This observation agrees with the finding 
that PTEN expression is lost in prostate cancer cells (McMenamin et al, 1999). 
Moreover, it was found in this study that prostatic epithelial cells developing low-
graded PIN or hypertrophy were moderately stained while those developing high-
graded PIN were not labeled with the PTEN antibody. As there is an association 
between high-graded PIN and carcinoma (Silvestri et al, 1995), the 
immunohistochemical expression of PTEN in the estrogen-imprinted and hormone-
treated Nb rat prostates is comparable to the finding of McMenamin et al (1999) in 
which loss of PTEN is correlated with advanced prostate disease and PTEN is 
expressed in all cases of PIN but lost in prostate cancer. Therefore, it may suggest 
that estrogen may initiate or progress the development of prostate cancer lesions in 
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the estrogen-imprinted and hormone-treated Nb rat by suppressing the expression of 
PTEN in the prostatic epithelial cells which in turn fails to regulate normal cell cycle 
progression. 
Together with the results obtained from the in vitro study, a consistent 
reduced PTEN expression was observed in the prostatic epithelial cells in vivo and in 
vitro. It may therefore be postulated that estrogen may initiate abnormal prostatic cell 
growth and tumorigenesis by suppressing PTEN expression. 
4.6.4 Alteration in Rap 1 
Rap 1 encoded by the Rap 1 gene (/?fl5-related tumor suppressor gene) (Wani 
et al, 1997), is a 21 kDa GTP-binding protein that shares 95% homology with Ras 
protein (Pizon et al, 1988). Rap 1 has an effector domain identical to the effector 
domain of Ras (Pizon et al, 1988). It is considered to be an antagonist of Ras as it 
can block Ras activation of the Ras effector, Raf-1, and form a non-productive 
complex (Bos et al, 2001; Caron, 2003) which would block transformation or 
suppress tumorigenesis. Although Rap 1 can bind to Raf-1 with a high affinity, Rap 1 
cannot activate Raf-1 as it does not allow Raf-1 phoshorylation that is necessary for 
full activity (Carey et al, 2003). Competition of Rap 1 with Ras gene products for 
downstream effectors or accessory molecules may keep Ras from eliciting a growth 
response (Wani et al, 1997). It is therefore suggested that Rap 1 can antagonize Ras 
action and suppress tumorigenesis. 
(a) In vitro study 
Rap 1 was expressed at a moderate level in the parental cells without estrogen 
exposure by immunohistochemistry. On the contrary, an increase in Rap 1 expression 
was induced in the cells transformed after estrogen treatment. Increased protein 
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expression of Rap 1 22 kDa) in the Ei-transformed cells by Western blotting 
further confirmed the increase in Rap 1 expression in the E2-transfomred cells. In the 
tumorigenicity study, injection of E2-transformed NRP-152 cells in nude mice 
developed no sign of tumor formation. It has been found that expression of Rap 1 
suppresses the tumorigenicity of the human hepatoma Hep3B cells (Lin et al, 2000). 
Therefore, from the in vitro results, it may suggest that NRP-152 cells may be first 
induced to up-regulate the expression of Rap 1 to suppress abnormal cell 
proliferation and transformation in the exposure of estrogen. This increased Rap 1 
expression in the Ei-tramsformd cells may also account for the failure in developing 
tumor in nude mice. Moreover, it may suggest that a longer period of estrogen 
treatment may be required for the NRP-152 cells to obtain tumorigeneicity. 
(b) In vivo study 
In the present study, a moderate cytoplasmic expression of Rap 1 was 
observed in the epithelial cells in the acini of the control Nb rat prostate whereas an 
altered expression of Rap 1 was detected in the prostatic epithelial cells of the 
estrogen-imprinted and hormone-treated rats. In the acini where premalignant lesions 
of hyperplasia and low-graded PIN were developed, positive Rap 1 expression was 
observed in the cytoplasm of the epithelial cells lining the lumen. A loss of Rap 1 
labeling was detected in high-graded PIN with tufting pattern and intra-acinar 
epithelial proliferation. As Rap 1 is related to the suppression of tumorigenesis (Lin 
et al, 2000), the detection of Rap 1 in the prostatic epithelial cells at the premalignant 
lesion areas suggests that cellular defense mechanism may be triggered by means of 
up-regulating the expression of tumor suppressor gene product, Rap 1，to inhibit 
abnormal cell growth induced by estrogen. However, when the damage of estrogen 
continues to exist, Rap 1 can no longer suppress the abnormal prostatic growth and 
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as a result lead to the progression of prostatic lesions. This may suggest that higher 
grades of prostate cancer lesions can be induced by estrogen through down-
regulating the expression of Rap 1. 
4.6.5 Alternation in BRCA2 
BRCA2 encoded by the tumor-suppressor gene, BRCA2, is a nuclear 
phosphoprotein (Wooster et al, 1994; Tavtigian et al, 1996). This protein is 
suggested to contain transcriptional activation domains (Milner et al, 1997)) and take 
part in the regulation of basic cellular progression, such as cell cycle progression, 
DNA repair pathway and maintenance of genomic integrity (Yuan et al, 1999). It is 
well-known that BRCA2 is involved in breast cancer development and mutation of 
BRCA2 has been found in up to 35% familial breast cancer (Stratton, 1996). An 
association between breast cancer and prostate cancer is supported and it has been 
reported that a higher risk of prostate cancer development is correlated with the 
family histology of breast cancer (Tulinius et al, 1992; Goldgar et al, 1994). It is also 
demonstrated that mutation in BRCA2 increases the risk of prostate cancer, 
particularly in the case early-onset disease (Isaacs et al, 2001). Besides, a study in the 
Iceland also shows that BRCA2 mutation accounts for all excess risk for prostate 
cancer (Tulinius et al, 2002). 
(a) In vitro study 
By immunohistochemistry, a strong positive nuclear expression of BRCA2 
was observed in the untreated parental NRP-152 prostatic cells whereas a decreased 
immunostaining pattern was observed in the E2-transformed cells. Western blot 
analysis of BRCA2 380 kDa) also demonstrated a decreased expression in the E2-
transformed NRP-152 cells. This decrease of BRCA2 expression is suggested to be 
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the triggered by the exposure of E! and thus the role played by BRCA2 as a tumor 
suppressor is lost under estrogen treatment. Increased BRCA2 expression was also 
observed in some of the E2-transformed clones of cells by Western blottings. This 
may suggest that BRCA2 are still able to act as a tumor suppressor in these cells in 
the exposure of estrogen. The various expressions of BRCA2 among the E2-
transformed cells by Western blottings may suggest that the various expressions of 
BRCA2 may be related to the degrees of prostate lesions induced by estrogen, 
(b) In vitro study 
Previous study on human prostate cancer by immunohistochemistry indicates 
that BRCA2 is undetectable in normal tissue (Edwards et al, 1998) but expression of 
BRCA2 can also be seen in the nuclei of the normal epithelium adjacent to tumor 
area (Edwards et al, 1998). In the present study, a moderate expression of BRCA2 
was seen in the nuclei of the epithelial cells in the control prostates. The present 
study disagrees with the previous findings. However, as the control rats were 
sacrificed at old age (> 12 months old), the rats might be susceptible to the 
development of age-related hyperplasia (Banerjee et al, 1998). The detection of this 
protein in the control prostate may suggest abnormal cell growth was inhibited by 
this tumor-suppressor protein. Previous report shows that 5/?CA2-lacking or mutant 
BRCA2 expressing mouse and human cells would suffer from defect in double-
stranded DNA breaks repairing (Connor et al, 1997; Abbott et al, 1998). Moreover, 
down-regulation of BRCA2 in prostate cancer is observed with the use of DNA-
damaging agents (Yuan et al, 1999). Therefore, the presence and late decrease of 
nuclear BRCA2 expression in the premalignant lesion (e.g. hyperplasia) developing 
areas in the estrogen-imprinted and hormone-treated prostates may suggest estrogen 
exposure may induce DNA damages that would lead to an up-regulation of BRCA2 
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for cytoprotection through faulty DNA repairing at the early onset of prostate cancer. 
It has been postulated that hypermethylation-mediated silencing may be responsible 
for the loss of gene expression in some sporadic cancer cases (Catteau et al, 1999; 
Magdinier et al, 1998). Therefore, the loss of BRCA2 expression in epithelial cells 
with high-graded PIN development may suggest that estrogen may lead to prostatic 
lesion development through hypermethylation-mediated silencing of BRCA2 gene, 
which in turn down-regulates BRCA2 expression for tumor-suppression function. 
4.6.6 Alteration in scavenger enzyme (Superoxide dismutase，SOD-1) 
Copper/zinc (Cu/Zn) superoxide dismutase (SOD-1) is an enzyme involved 
in cellular oxygen metabolism (Marikovsky et al, 2002). It is a metalloprotein which 
functions as a dimer of two identical subunits with each subunit containing one Zn 
and one Cu atom (Orrell et al, 1995). SOD-1 is expressed in somatic cells and is 
important in cellular oxygen metabolism (Orrell et al, 1995). SOD-1 is responsible 
for the dismutation of the superoxide radicals into hydrogen peroxide and dioxygen 
(Fridovish, 1978) to get rid of the toxic superoxide radicals. Defects in gene 
encoding SOD-1 are involved in some neurological disease, e.g. Alzheimer disease, 
with an increase in neurotoxicity and motor neuron death (Shaw et al, 1998). 
Previous studies have found that SOD-1 protein and activity are decreased in human 
fibroblasts after being infected by SV 40 (Bravard et al, 1992). 
(a) In vitro study 
A decrease in the SOD-1 expression was detected in the E2-transformed 
clones, as compared to the parental NRP-152 cells by immunohistochemistry. 
Moreover, the detection of SOD-1 20 kDa) by Western blottings illustrated a 
reduced expression of this protein in the E2-transformed cells (clone no. 2 and 3). A 
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Study on human fibroblasts also indicates an early SOD-1 protein loss during SV40-
transformation (Bravard et al, 1992). Therefore, it may postulate that loss of this 
scavenging enzyme is resulted after estrogen exposure. However, in E2-transformed 
clone no. 1 and 4，an increased expression was observed by Western blottings. This 
observation may suggest that expression of SOD-1 is up-regulated in some of the 
prostatic cells to protect themselves from oxidative damage in the exposure of 
estrogen, 
(b) In vivo study 
In the present study, it was found that the expression of SOD-1 was observed 
in the prostatic nuclei of the epithelial cells lining along the acini in the control rats. 
This suggests that under normal condition, the prostatic epithelial cells possess this 
scavenger enzyme for cellular defense to catalyze superoxide radicals produced by 
aerobic metabolism. In the estrogen-imprinted and hormone-treated Nb rat prostates, 
SOD-1 was also observed in the nuclei of some of the epithelial cells in the non-
lesion areas. Meanwhile, a general lost of SOD-1 labeling was seen in the epithelial 
cells when hypertrophy, low-graded PIN and advanced lesion of carcinoma in situ 
were developed. 
Marikovsky et al (2002) finds that alteration in the activity of SOD-1 may 
affect angiogenesis and angiogenesis-dependent pathologies. Reoxygenation is 
continuous during angiogenesis and reactive oxygen species (ROS) is produced. 
Increased expression of human SOD-1 in transgenic mice leads to the formation of 
new blood vessels whereas administration of disulfiram (DSF), an inhibitor of SOD-
1, inhibits angiogenesis (Marikovsky et al, 2002). It shows that the formation of 
blood vessel formation is achieved by the increased amount of SOD-1 by scavenging 
the increased amount of superoxides during angiogenesis. Decreased SOD-1 
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expression is related to the failure in angiogenesis, implying that the endothelial cells 
cannot confront the increased level of ROS with a reduced amount of superoxides 
(Marikovsky et al, 2002). 
The present study may suggest that the cells being unaffected by the exposure 
of estrogen preserve the ability to act against the oxidative damage. On the contrary, 
estrogen may down-regulate the expression of SOD-1 in the prostatic cells and lead 
to prostate lesion development. With a reduced expression of SOD-1, the cells lose 
their abilities to scavenge ROS which is produced intracellularly or produced during 
the administration of estrogen during estrogen imprinting and combined hormone 
treatment. As a result, estrogen-induced ROS may cause oxidative damages to the 
DNA and cellular macromolecules such as proteins and lipids (Cavalieri et al, 2000) 
and result in the development of prostatic lesions. 
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Chapter 5. Summary 
5.1 In vitro study 
1. Transformation of the normal immortalized and non-tumorigenic rat 
epithelial cells, NRP-152, by 17p-estradiol (E2) was demonstrated by colony 
formation in soft agar with a higher colony-forming efficiency than the 
parental cells, altered cell morphology and loss of cell-cell contact inhibitions 
in E2-transformed NRP-152 cells. However, the E2-transformed NRP-152 
cells failed to grow as tumor in the nude mice by the inoculation of cells, 
suggesting that prolonged estrogen treatment might be required for 
carcinogenesis. 
2. From the study of the two cDNA microarrays, four genes with a simultaneous 
difference and up-regulated or down-regulated gene expression were selected 
and further verified by protein analysis. These genes included TUBAS, PTEN, 
RAPIA and BRCA2. 
3. By electron microscopy, the ultrastructure of the E2-transformed cells was 
altered. These included distorted mitochondria with focal loss of infoldings in 
the inner membrane and cristae, increase in the amount of matrix, distorted 
nuclear membrane, increase in the number of secondary lysosomes and 
alteration in cytoskeletal structure, suggesting that these organelles might be 
damaged by the reactive oxygen species (ROS) formed during the 
metabolism of estrogen in the E2-transformed NRP-152 cells. 
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4. A slight increased expression of ERa (native ERa) was observed by Western 
blotting, suggesting estrogen may amplify its effects via the increased number 
of ERa The expression of ERp and AR were decreased in the E2-transformed 
prostatic epithelial NRP-152 cells by immunohistochemistry and Western 
blotting. The decrease in ERp expression showed that the antiproliferative 
function was interfered. The reduced expression of AR suggested that 
androgen might not be predominantly regulated by AR as the parental NRP-
152 cells. 
5. The expression of tubulin-a was significantly reduced in the E2-transformed 
NRP-152 cells by immunohistochemistry, immunofluorescence and Western 
blottings. Together with the finding of increased doubling time in the E2-
transformed cells, these findings showed that transformation of cells might be 
due to the formation of disrupted microtubules and affected chromosomal 
separation during mitosis as a result of estrogen treatment. 
6. By immunohistochemistry and Western blottings, the expression of PTEN in 
the E2-transformed NRP-152 cells was reduced. The result suggested that the 
ability to negatively regulate the cell growth by PTEN was lost after estrogen 
exposure. 
7. Increased expression of BRCA2 in some of the clones as detected by Western 
blottings suggested BRCA2 might act as a tumor suppressor in these cells. 
The decreased expression of BRCA2 protein suggested that the cellular 
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protective mechanism to genome instability was lost in some of the E2-
transformed cells. 
8. An increase in expression of a Ras-related tumor suppressor gene protein, 
Rap 1， was detected in the E2-transformed NRP-152 cells by 
immunohistochemistry and Western blottings. This suggested that a cell 
defense mechanism was triggered at the initiation of transformation or tumor 
development. Besides, increased Rap 1 expression in the E2-transformed cells 
might account for the failure in developing tumors in nude mice. 
9. By immunohistochemistry and Western blottings, various expressions of the 
scavenger enzyme, SOD-1, were observed in the Ez-transformed NRP-152 
cells. During transformation by E2, an antioxidant defense mechanism might 
be triggered in some of the cells, as shown by the increased expression of 
SOD-1. Down-regulation of the SOD-1 expression was also observed in some 
of the cells in which transformation was favored. 
5.2 In vivo study 
1. Various grades of epithelial proliferative lesions including hyperplasia, PINs 
and carcinoma in situ were observed in the ventral prostate (VP) and the 
lateral prostate (LP) in the perinatal estrogen-imprinted and long-term 
hormone-treated Nb rats. Besides, inductions of PIN and neoplasstic lesions 
were observed in the dorsal prostate (DP) where lesions were rarely 
developed by the usual single long-term hormonal treatment. Based on this 
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observation, we suggested that estrogenization of prostate gland during early 
development might accelerate the process of hormone-induced 
carcinogenesis. 
2. By immunohistochemistry, we demonstrated that stromal ERa expression 
was increased whereas both ERp and AR expression were decreased. The 
increased expression of stromal ERa and decreased expression of ERP and 
suggested that the prostates of these estrogen-imprinted and hormone-treated 
Nb rat prostate might be predominantly regulated by estrogen via ER rather 
than androgen. 
3. Decreased expression of tubulin-a in the perinatal estrogen-imprinted and 
hormone-treated Nb rat prostates, especially in high-graded PIN and 
carcinoma in situ, suggested that estrogen might lead to prostate lesions by 
reducing the amount of tubulin-a. 
4. Abil ity of negatively regulating the cell growth and/or proliferation might be 
affected after estrogen treatment as indicated by the decreased expression of 
PTEN in the Nb rat prostates after perinatal estrogen-imprinting and hormone 
treatment. 
5. Increased Rap 1 expression in hyperplasia and low-graded PIN might suggest 
that cellular defense mechanism was triggered in the initiation of prostatic 
lesions. The decrease in Rap 1 expression observed in high-graded PIN might 
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suggest that estrogen might lead to higher grade of prostate lesions by down-
regulating Rap 1 expression. 
6. Up-regulated expression of BRCA2 in premalignant lesions might suggest 
that cytoprotection was triggered in the cell at early onset of prostate lesions 
while the lost of BRCA2 expression in high-graded PEN suggested that 
estrogen might lead to prostate lesions by suppressing the expression of 
BRCA2. 
7. Reduced expression of SOD-1 in cells developing prostatic lesions showed 
that estrogen might lead to the prostate lesions through the loss of ROS 
scavenging ability in prostatic cells. Presence of SOD-1 in the prostatic 
epithelial cells of the estrogen-imprinted and hormone-treated rats suggested 
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